AUTHOR INDEX

Abe, S. 47, 52
Abonyi, M. 2, 11, 14, 20
Abumrad, N. A. 174, 177–178
Accossato, P. 112, 115
Acheson, K. J. 163, 176
Ackerman, J. J. 102, 114
Adachi, Y. 272, 280
Adair, S. 251, 261
Adams, W. B. 229, 231, 247
Aggerbeck, L. P. 180, 197
Agius, L. 184, 191, 197–198
Agrawal, K. C. 55–56, 64, 66–68
Ahmad, I. 236, 238, 249
Ahn, N. G. 206, 226
Ailhaud, G. 164, 176
Akiyama, T. 210, 226
Albers, S. 131, 145
Alger, J. R. 102, 113
Ali, R. 131, 145
Allan, P. 253, 261
Allegrini, S. 251, 261
Allen, P. G. 217, 219, 227
Allen, T. 239, 249
Allman, R. F. C. 174, 177
Alper, C. A. 70, 88
Altman, N. 259, 263
Altschuler, E. 274, 276, 281
Alvarez, O. 294, 301
Amanuma, H. 37, 41
Ampe, C. 200–201, 204, 213, 225
Anderson, G. R. 112, 115
Anderson, J. E. 69, 86
Anderson, M. 179, 196
Anderson, N. G. 320, 337
Anderson, R. A. 5, 21
Andre, L. 213, 227
Andres, R. 166, 177
Andrews, P. A. 118, 128
Angelin, B. 179, 196
Antequera, J. 258, 262
Antoni, F. 70, 88
Araf, T. 39, 41
Arai, H. 118, 128–129
Arch, J. R. S. 191, 198
Ardawi, M. S. M. 131, 137, 144, 146
Argiles, J. M. 111, 115
Argos, P. 233, 234, 248
Arnér, E. S. J. 70, 87–88
Arnvig, K. 229, 237, 247
Asai, T. 229, 247
Astaldi-Ricotti, B. 273, 280
Astaldi-Ricotti, G. C. 272, 280
Atema, A. 102, 114
Atkinson, D. E. 134, 146
Atsumi, S. 50, 53
Augsten, T. R. 137, 146
Avramoglu, R. K. 175, 178
Avruch, J. 203, 226
Azain, M. J. 184, 197

Babbs, C. F. 102, 114
Bachur, N. R. 118, 120, 128, 130
Backer, J. M. 50, 53
Bagnara, A. S. 229, 246
Bakay, B. 235, 248
Baker, R. M. 91, 98, 100
Bakker, M. 252–253, 261
Balcarek, J. M. 321–323, 338
Baldo, A. 175, 178
Balis, M. E. 232, 248
Balkwill, F. 296–297, 301
Ballas, L. M. 180, 197
Balo-Banga, J. M. 229, 247
Baltimore, D. 36, 41
Banfic, H. 24, 25, 28–30, 32–33
Barber, T. A. 183, 197
Barltrop, J. A. 56, 58, 68
Barnabei, O. 24–25, 28–29, 32
Barnella, U. S. 174, 177–178
Bar-On, H. 187, 198
Baronzio, G. F. 112, 115
Barr, F. A. 289, 292
Bartels, C. J. 91, 98, 100
Barthel, A. 283, 284, 286, 292
Bartlett, S. M. 180–182, 197
Bartoli, S. 23, 31
Bartoszek, A. 118, 129
Bartus, H. F. 266, 270, 273, 279
Bashford, C. L. 111, 115
Batist, G. 98, 100
Batra, J. K. 272, 274, 280
Batty, I. R. 18, 21
Bavarel, G. 134, 146
Bavelloni, A. 30, 33, 272–273, 280
Bawden, L. 296, 297, 301
Baylin, S. 258–259, 262
Bazenet, C. E. 5, 21

Beall, H. D. 118, 129
Beam, C. 117, 127
Beattie, J. 316, 318–319, 329, 337–338
Beavo, J. 305–306, 319–321, 323, 334, 338
Beck, W. T. 266, 267, 269–271, 274, 276, 279–281
Becker, M. A. 229–231, 235, 239, 245, 247–249
Beehler, B. C. 91, 98, 100
Beggs, J. D. 118, 129
Beggs, M. 147, 158, 161
Begleiter, A. 118, 129
Behar, K. L. 102, 113
Belch, A. 251, 261
Belfrage, P. 165, 173–174, 306, 320, 334
Bell, A. 175, 178
Bell, G. 235, 239, 248
Bell, R. M. 180, 197
Bellamy, A. S. 117, 118, 124, 128
Benavente, R. 273, 280
Bender, T. P. 37, 41
Bennet, Jr, L. 253, 261–262
Bennett, M. K. 283, 291
Bensch, P. A. 146
Beran, M. 270, 280
Berezney, R. 265, 276, 278–279, 281
Bergmeyer, H. U. 104, 114
Bergstrom, J. 131, 137, 144
Berridge, M. J. 29, 32
Berrios, M. 266, 279
Bertagnolo, V. 24–25, 28–30, 32–33
Bertino, J. R. 55–56, 67
Bertone, V. 112, 115
Bessard, T. 163, 176
Bestango, M. 272, 280
Bethune, V. 55–56, 67
Bhujwalla, Z. M. 102–104, 107, 113–114
Bianchi, V. 69, 85–86
Biggs, S. 146
Billi, A. M. 24–25, 28–29, 32–33
Bird, A. 258, 262
Birkett, L. 251, 261
Birnbaumer, L. 312, 334
Bizanek, R. 118, 128
Bjorge, S. 91, 95, 98, 100
Blackshear, P. J. 184, 197
Blanchette-Mackie, E. J. 174, 177
Blanz,Jr, E. J. 55–56, 67
Blick, M. 270, 280
Bligh, H. F. J. 118, 129
Blinderman, L. 180, 197
Bloch, A. 35, 37, 40–41
Bodell, W. 251, 261
Boer, P. 230, 247
Bohman, C. 70, 87
Bökkerink, J. 252–254, 261–262
Boland, O. 166, 169, 171–173, 177
Bolger, G. 306, 321–323, 334
Bollen, M. 221, 227
Bolognino, M. 182, 197
Bondjers, G. 192, 198
Bonora, B. 23, 31
Boone, T. 297, 301
Boonstra, J. 29, 32
Bootsma, D. 70, 88
Bor-N, J. 192
Borchardt, R. 257, 262
Borelli, E. 289, 292
Borén, J. 179, 196, 198
Borgström, B. 165, 173–174, 177
Bosch, M. 222, 227
Boss, G. R. 229–230, 247
Bosze, P. 2, 21
Botstein, D. 266, 279
Bouma, M.-E. 180, 197
Bower, S. G. 239–240, 249
Boy de la Tour, E. 272, 280
Boyer, M. J. 102, 114
Boyles, J. 258, 262
Brada, Z. 259, 263
Bradford, N. M. 133, 137, 145
Bradshaw, Jr, H. D. 70, 87
Braunschweiger, P. G. 104, 114
Brautigan, D. L. 203, 225
Brenner, S. L. 214, 227
Bresnick, E. 11, 21
Breton, M. 29, 32
Brindley, D. N. 191, 198
Brockman, H. L. 165, 174, 177
Brockman, J. L. 5, 21
Brockman, R. W. 55–56, 67, 253, 262
Brooks, B. 191, 198
Brooks, D. P. 316, 337
Brosjö, O. 70, 87
Brosnan, J. T. 131, 134, 144, 146
Brosnan, M. E. 134, 146
Brown, N. 321, 337
Brown, P. D. 296–297, 301
Brown, R. A. 131, 144
Brown, T. R. 18, 21
Brox, L. 251, 261
Brumley, J. L. 73, 89
Brunton, L. L. 335
Buchanan, J. M. 229, 246–247
Buckley, J. 258, 262
Bugg, B. Y. 274, 276, 281
Bulba, S. 259, 263
Burchell, B. 91, 98, 100
Burchenal, J. H. 55–56, 67
Burke, P. 258–259, 262
Burn, R. 117, 127
Burnham, F. J. 183–184, 197
Bushfield, M. 310–316, 319, 335–337

Cady, E. 101–102, 113
Cahill, G. F. 175, 178
Cainflone, K. 175, 178
Calabretta, B. 39, 41
Camici, M. 251, 261
Camitta, B. 251, 261
Campbell, D. G. 203, 225
Cantley, L. C. 5, 21
Capitani, S. 23–25, 28–33
Capizzi, R. L. 66, 68
Carini, C. 30, 33
Carmichael, D. 294, 301
Carpenter, C. L. 5, 21
Carraro, F. 170, 177
Carrascosa, J. M. 210, 226
Carson, D. A. 69, 86
Carter, S. B. 91, 100
Cartwright, I. J. 180, 197
Caruso, M. 71, 88
Casper, J. 251, 261
Cassagne, C. 193, 198
Castell, J. V. 70, 87
Cataldi, A. 25, 29, 32
Catapano, C. V. 271, 277, 280–281
Cattano, C. 132, 145
Caudwell, F. B. 203, 226
Cayla, X. 222, 227
Celis, J. 207, 226
Celotti, L. 69, 85–86
Cerino, A. 272, 280
Cerniglia, G. J. 110, 115
Cesar, D. 147, 159, 162
Chabner, B. 251, 261
Chambers, D. A. 229, 247
Chan, D. 270, 280
Chan, E. Y. W. 193, 198
Chang, Z. F. 71, 83, 85, 89
Chao, F.-F. 184, 197
Chaponnier, C. 200, 225
Charles, H. C. 117, 127
Chatterton, J. E. 180, 197
Chen, J. H. 38, 41, 316, 337
Chen, L. H. J. 146
Chen, T. M. 39, 41
Chen-Liu, L. W. 180, 197
Cheng, Y.-C. 73, 89, 117, 127
Chiesa, R. 272, 280
Chikenji, T. 229, 230, 247–248
Chirivi, R. 296, 297, 301
Chiu Yen, R.-W. 258, 262
Choi, W. C. 28, 32
Chomczynski, P. 36, 40
Chowdary, D. 118, 128
Christensen, H. N. 132, 145
Christiansen, M. 163, 176
Christie, N. 251, 261
Christophe, J. 311, 335
Chumley, S. 253, 262
Chung, T. D. Y. 266, 270, 279–280
Cianflone, K. 175, 178
Ciccarelli, E. 311, 335
Ciejek, E. M. 265, 278
Cieslinski, L. B. 321, 322, 323, 338
Cihák, A. 259, 263
Cinti, C. 30, 33
Cirtain, C. A. 267, 269, 276, 279
Civin, C. 251, 261
Clark, M. L. 166, 169, 171–173, 177
Clarke, D. J. 91, 98, 100
Cline, J. C. 91, 100
Cloos, L. 70, 73–79, 81–83, 87–88
Cocco, L. 23–25, 28–33
Cockerill, P. N. 266, 279
Cockroft, S. 28, 32
Coffey, D. S. 265, 266, 273, 278–279
Coghlan, V. M. 306, 335
Cohen, F. 69, 86
Cohen, M. B. 97, 100
Cohen, P. 140, 146, 203, 225–226
Colbourne, S. A. 134, 146
Coleman, R. A. 180, 197
Collins, J. M. 265, 279
Coloma, J. 70, 87
Combs, K. A. 180, 197
Condeelis, J. S. 200, 225
Confer, G. 117, 127
Connell, J. M. C. 315, 336
Connelly, A. 103, 114
Conrad, S. E. 71, 88
Constantinides, P. O. 121, 130
Conti, M. 306, 321, 334
Cook, J. M. 91, 100
Cook, P. R. 265, 278
Cooke, C. A. 266, 279
Cooper, D. M. F. 316, 337
Cooper, J. A. 200, 217, 225, 227
Cooper, M. 306, 321, 334
Coppack, S. W. 165–173, 177–178
Coppock, D. L. 71, 88
Cornell, N. W. 133, 146
Corvera, S. 133, 143–145
Cory, A. H. 56–58, 60–61, 67–68
Cory, J. G. 56–61, 64, 66, 67–68
Cosby, L. A. 56, 68, 117, 128
Cosgrove, L. 73, 89
Covey, J. 251, 261
Cowan, K. H. 98–100
Crabb, D. W. 147–149, 151, 152, 156, 162
Crabtree, B. 131, 144, 175, 178
Cragoe Jr, E. J. 102, 114
Craig, R. W. 35, 40
Creasey, W. A. 55–56, 66–68
Creasin, D. 259, 263
Creemers, G. 293, 300

Crimmin, M. 296–297, 301
Crissman, J. 294, 301
Crofton, J. T. 316, 337
Crooke, S. T. 266, 270, 273, 279
Cunningham, C. C. 107, 115

D'Incalci, M. 251, 261
Da Costa, T. H. M. 165, 177
Daino, L. 259, 263
Dalton, W. S. 274, 281
Damen, F. 252–253, 261
Damgaard, S. E. 192, 193, 198
Danks, M. K. 266–267, 269–271, 274, 276, 279–281
Davies, B. 297, 301
Davis, R. L. 323, 338
De Abreu, R. 252–254, 261–262
De Boeck, S. 207, 226
De Corte, V. 201–203, 205, 206, 225
De Korte, D. 251, 260
De Marco, D. 251, 261
De Ville, Y. 200–204, 206–208, 210–211, 213–214, 218–220, 225
De Vries, A. 230, 247
de Wit, I. S. C. 29, 33
Debeer, L. J. 188, 198
Debustros, A. 258, 262
Declerck, Y. 294, 297, 301
Deconti, R. C. 55, 56, 67
Defendi, V. 39, 41
Deffie, A. M. 272, 274, 280
Defronzo, R. A. 166, 177
Degerman, E. 306, 320, 334
DeGroot, L. J. 134, 138, 146
Deguchi, A. 45, 52
Deininger, P. L. 70, 87
Deisseroth, K. 274, 276, 281
Dekker, L. V. 217, 227
Del Corso, A. 251, 261
Delistre, V. 91, 100
Delong, D. C. 91, 100
Den Breejen, E. 251, 260
Deneka, D. A. 267, 276, 279
Denstman, S. 35, 37, 40–41
Dent, P. 203, 225–226
Denton, R. M. 139, 146
Denyer, G. S. 147, 157, 159, 162
DeShepper, P. J. 188, 198
Deuel, T. F. 229, 233, 237, 242, 247, 249
DeVita, V. 293, 300
Dewhirst, M. 117, 127
Dhof, T. C. 217
Diadone, M. 251, 261
Diano, L. 259, 263
Dicker, P. 229, 247
Dickey, B. 312, 334
Dijkwel, P. A. 265, 276, 279
Dinardo, S. 266, 279
Dipple, I. 308, 335
Divecha, N. 23–25, 28–33
Dixon, C. W. 184, 197
Dixon, G. 253, 262
Dixon, J. L. 179, 196
Dizik, M. 259, 263
Dobson, G. P. 104, 107–108, 111, 114
Domenget, C. 39, 41
Donohue, J. 251, 260
Dorf, M. 70, 88
Dorman, T. E. 266, 279
Doskeland, S. O. 140, 146
Dostmann, W. G. R. 140, 146
Douglas, T. 70, 88
Doyle, T. W. 122, 130
Drake, F. H. 266, 270, 272–273, 279–280
Drake, S. 251, 261
Dubendorff, J. W. 72, 89
Duerden, J. M. 180–184, 187, 197
Dulmadge, E. 253, 262
Dunn, J. J. 72, 89
Dupont, B. 72, 89
Dutreix, J. 117, 127
Dutrillaux, B. 70, 87

Earnshaw, W. C. 266, 272, 279–280
East, N. 297, 301
Eastwood, S. L. 231, 248
Eble, J. N. 2, 21
Ebuchi, M. 70, 88
Ecke, M. 210, 226
Eckel, R. H. 164, 176
Eckhardt, S. 2, 21
Edens, N. K. 174, 178
Edwards, K. A. 272, 280
Edwards, R. H. T. 101–102, 113
Egelrud, T. 173, 177
Egerton, M. 321–322, 337
Ehrlich, C. E. 2, 21
Ehrlich, G. 258, 262
Eichinger, L. 213, 217–218, 227
Eisenstein, R. S. 147, 158, 161
Elia, M. 170, 177
Ellims, P. H. 70, 73, 87, 89
Elliott, A. J. 118, 129
Elliott, K. R. F. 308, 335
Elovson, J. 180, 197
Emmison, N. 191, 198
Emrani, J. 2, 20
Endo, A. 50, 53
Eng, W.-K. 274, 281
Erbe, J. 82, 85, 89
Erikson, E. 203, 226

Eriksson, S. 70, 73, 74, 87–88
Erwin, M. J. 229, 246
Espinal, J. 147, 158, 161
Estabrook, R. W. 120, 130
Esterman, M. A. 91, 95, 100
Estey, E. 70, 87
Etcubanas, E. 55–56, 67
Evans, R. D. 166, 168, 177
Evelhock, J. L. 102, 114
Ewart, H. S. 134, 146
Ezzel, R. M. 200, 225

Faderan, M. A. 12, 21, 131, 144
Fain, P. 70, 87
Faix, D. 147, 159, 162
Falls, K. M. 266, 279
Falquet, J. 272, 280
Farkas, B. K. 112, 115
Farr, A. L. 58, 68
Faßhauer, D. 283, 284, 286, 292
Fearon, E. 258, 262
Fechheimer, M. 212, 227
Feo, F. 259, 263
Fernandes, D. J. 265–267, 269–274, 277–281
Fernandez, A. 306, 335
Ferro-Novick, S. 283, 291
Fewer, K. 133, 146
Fielding, B. A. 166, 169, 171–174, 177
Finch, L. R. 229, 246
Fiol, C. J. 203, 225
Firtel, R. A. 210, 226
Fischer, D. B. 118, 124, 129–130
Fischer, J. J. 118, 124, 129–130
Fisher, J. 118, 129
Fisher, P. A. 266, 279
Fisher, R. M. 166, 168, 170, 177
Flaks, J. G. 229, 246
Flatt, J. P. 163, 176
Fleischer, S. 232, 248
Flemington, E. 70, 87
Fleron, P. 192–193, 198
Forest, C. 174, 178
Foster, D. 146
Foster, K. A. 265, 279
Fox, I. H. 229, 237, 242, 246–247, 249
Fracasso, P. M. 117–118, 128
Francone, O. L. 187, 188, 191, 198
Frankenfield, C. D. 303–304, 334
Franklin, T. J. 91, 100
Frayn, K. N. 165–174, 177–178
Fredrikson, G. 165, 174, 177
Freitas, I. 112, 115
French, F. A. 55–56, 67
Friche, E. 269, 276, 280–281
Fritsch, E. F. 149, 162
Fu, X. 297, 301
Fukuda, N. 184, 197
Fullerton, F. 259, 263
Funovics, J. 131, 137, 145
Furst, P. 131, 137, 145
Furuhashi, K. 201, 210–211, 213, 215, 217, 225–226
Futscher, B. W. 276, 281

Gan, T. E. 73, 89
Gandhi, V. 70, 87
Garcia-Sainz, J. A. 133, 143–145
Garofalo, A. 296–297, 301
Garrard, W. T. 266, 279
Garvin, L. J. 91, 100
Gaspa, F. 259, 263
Gasser, S. M. 266, 272, 279–280
Gawler, D. J. 311, 315, 319, 335–336
Gazdar, A. 258, 262
Gebhard, W. 211, 223, 226
Gebhardt, R. 132, 145
Gee, M. V. 118, 120, 128, 130
Geist, L. J. 39, 41
Genieser, H.-G. 140, 146
George, C. B. 57, 68
Gerisch, G. 210, 226
Gerweck, L. E. 102–103, 114
Gesser, B. 207, 226
Gessner, T. 35, 40, 91, 98, 100
Gettemans, J. 200–208, 210–211, 213–214, 218–220, 225
Gewirtz, A. M. 39, 41
Giaever, G. N. 266, 279
Giavazzi, R. 296–297, 301
Gibbons, G. F. 166, 168, 170, 177, 179–184, 187, 189, 196–198
Giblett, E. R. 69, 86
Gibson, K. J. 229, 247
Gibson, N. W. 118, 129
Gill, C. M. 180, 197
Gillies, R. J. 102–103, 114
Gilman, A. 293, 300
Gilmour, R. S. 23–25, 28–33
Ginsberg, H. N. 179, 196
Giovane, A. 38, 41
Glazer, R. I. 99, 100
Glover, C. J. 118, 128
Glover, J. 251, 261
Glusenkamp, K. H. 102, 114
Goff, S. P. 71, 88
Golay, J. 39, 41
Goldenberg, G. J. 272, 274, 280
Goldfarb, S. 183, 197

Goldschmidt-Clermont, P. J. 217–218, 227
Goodwin, G. W. 148, 158, 159, 162
Goonesekere, N. C. W. 211, 223, 227
Gordon, D. A. 180, 197
Gordon, R. E. 101–102, 113
Gordon, S. L. 118, 120, 128, 130
Goris, J. 217, 221–222, 227
Goss, S. J. 235, 248
Goto, T. 266, 279
Gougoux, A. 131, 144
Goz, B. 117, 127
Graham, M. 251, 261
Graham, R. A. 18, 21
Grant, F. J. 146
Granzen, B. 276, 281
Graslund, A. 64, 66, 68
Grazi, E. 210, 226
Green, C. 193, 198
Greengard, O. 85, 89
Gregg, R. E. 180, 197
Gregoire, V. 70, 87
Grey, A.-M. 313, 336
Griffaton, G. 187–188, 191, 198
Griffini, P. 112, 115
Griffiths, J. R. 101–104, 106–108, 113–115
Griffiths, S. L. 316–317, 319, 337
Grindey, G. B. 70, 87
Gross, M. K. 71, 88
Grundel, S. 132, 145
Guan, X.-P. 35, 40
Gudi, R. 149, 153–154, 156–157, 162
Gunvén, P. 70, 87
Gustafson, D. L. 118, 129
Gusterson, B. A. 106, 114
Guttman, A. 70, 88
Guynn, R. W. 104, 106–107, 114

Haffty, B. G. 118, 124, 129–130
Hahn, S. L. 38, 41
Hales, P. 191, 198
Halestrap, A. P. 133, 139, 145–146
Hall, B. 133, 146
Hall, F. L. 203, 225
Halligan, B. D. 272, 279
Halligan, W. B. 266, 280
Hallmann, R. 200–201, 210, 213, 225
Halperin, M. L. 131, 134, 144, 146
Halvorson, H. R. 107, 115
Hamada, M. 13, 21, 44–49, 52–53
Hamelehle, K. L. 91, 95, 98, 100
Hamilton, S. 258, 262
Hamlani, R. 166, 169, 171–173, 177
Hamlin, J. L. 265, 276, 278
Hammarqvist, F. 131, 145
Hammond, V. A. 169, 177
Hance, A. 112, 115
Handlogten, M. E. 132, 145
Hanei, M. 233–234, 248
Hanks, S. K. 208, 226
Hanski, E. M. 311, 313, 319, 336
Hardie, D. G. 203, 225
Harker, W. G. 274, 276, 281
Harlow, E. 269, 280
Harlow, K. W. 229, 233–234, 239–240, 247, 249
Harmon, C. M. 174, 177
Harper, A. E. 147, 158, 161
Harris, M. B. 85, 89
Harris, R. A. 147–149, 151–154, 156–159, 161–162
Hartwig, J. H. 200, 225
Hasegawa, T. 200, 213, 225
Hashimoto, Y. 2, 20
Hata, Y. 2, 11, 14, 20
Hatano, S. 200, 201, 210, 211, 213, 215, 217, 225–226
Hattori, S. 45, 52
Haussinger, D. 131, 132, 144–145
Haveman, J. 101, 104, 113
Haverkort, W. 251, 260
Hayashi, C. 46, 48, 49, 52–53
Hayashi, H. 200, 213, 225
Hayes, J. S. 335
Hebbachi, A.-M. 180, 197
Heck, M. M. S. 266, 279–280
Heidler, S. 235, 239, 248
Heimberg, M. 184, 197
Heimbrook, D. C. 118, 121, 128, 130
Heinemann, V. 70, 87
Heiss, S. G. 217, 227
Hellerstein, M. K. 147, 159, 162, 176
Hellerstein, N. S. 163, 176
Hellman, S. 293, 300
Hellstrom, I. 102, 114
Hellstrom, K. E. 102, 114
Helms, B. 29, 32
Helpern, J. A. 107, 115
Hemington, J. G. 111, 115
Hems, R. A. 133, 146
Henderson, J. F. 229, 247, 253, 262
Henderson, R. 253, 262
Hendrickson, N. 239, 249
Hermier, D. 191, 198
Hertel, L. W. 70, 87
Hesse, J. 200, 201, 210, 213, 225
Heyworth, C. M. 307–308, 310–311, 313, 319–320, 335–337
Hickson, D. 118, 129
Higgins, J. A. 180, 197
Higo, H. 37, 41
Hilden, H. 164, 176

Hill, B. T. 117–118, 124, 128
Hill, D. 253, 261
Hill, L. 102, 114
Hill, M. 259, 263
Hinds, M. 270, 274, 276, 280–281
Hiramatsu, T. 51, 53
Hirsch, J. 174, 178
Hirschberg, D. L. 102, 114
Hnilica, L. S. 265, 278
Hoang, B. 175, 178
Hockaday, T. D. R. 166, 168, 177
Hockel, M. 110, 115
Hodnick, W. F. 118, 129
Hoffbrand, A. V. 85, 89
Hoffman, D. H. 91, 95, 100
Hoffman, R. 257, 262, 297, 301
Hofmann, A. 213, 227
Hofmann, G. A. 266, 270, 273, 279–280
Hofsteenge, J. 203, 226
Hokin, L. E. 4, 21
Holden, L. 85, 89
Holm, C. 266, 279
Holmes, C. F. B. 140, 146
Holmes, E. W. 229, 246
Holmes, K. C. 211–212, 223, 226
Holness, M. J. 147, 159, 162
Holstege, A. 229, 247
Homan, R. 91, 95, 98, 100
Honma, Y. 47, 52
Hoover, K. 259, 263
Höppener, J. 258, 262
Hori, M. 50, 53
Hori, T. 47, 52
Horton, Y. 321–323, 337
Houslay, M. D. 141–142, 146, 303–308, 310–317, 319–325, 329, 331, 334–338
Hove-Jensen, B. 229, 233–234, 237, 239–240, 247, 249
Howard, P. K. 210, 226
Howard, R. M. 147, 159, 162
Howe, F. A. 102–104, 106–108, 113–114
Hoy, C. 117, 128
Hozumi, M. 47, 52
Hromchak, R. 35, 40
Hruby, V. J. 141–142, 146, 309–311, 313, 335
Hsiang, Y. H. 267, 270, 280
Huang, D. Y. 71, 83, 85, 89
Huang, P. 70, 87
Hubbard, M. J. 203, 225
Huber, L. A. 283, 284, 286, 292
Hughes, C. S. 118, 128
Hughes, P. J. 4, 21
Huisman, T. 70, 88
Huisman, W. H. 229, 231, 247
Hulscher, T. 252–253, 261
Hummel. J. J. 51, 53
Humphreys, S. M. 165, 167–174, 177–178
Hunninghake, G. W. 39, 41
Hunter, T. 208, 226
Huttner, W. B. 289, 292
Huttunen, J. K. 164, 176
Hwang, W. 183, 197
Hwant, Y. C. 102, 114

Ichikawa, S. 2, 20
Iinuma, H. 46–47, 52–53
Iitaka, Y. 44, 46, 52
Iiunma, H. 48, 53
Iizasa, T. 230, 233–236, 239, 241, 248–249
Ikawa, Y. 37, 41
Ikeda, D. 46, 52
Ikegami, T. 2, 20
Iles, R. A. 101, 102, 113
Imahori, K. 207, 226
Imaoka, T. 45, 46, 52
Imoto, M. 13, 21, 44–49, 51–53
Inoue, K. 184, 197
Intko, J. 184, 197
Introna, M. 39, 41
Inui, T. 118, 128
Ipata, P. 251, 261
Iracki, T. 118, 128
Irvine, R. F. 18, 21, 23–25, 28–33
Irwin, J. 148, 158–159, 162
Isenberg, G. 200–201, 210–211, 213, 215, 225–226
Ishijima, S. 230, 233–236, 238–239, 241–243, 248–249
Ishizuka, T. 229–231, 233, 236, 247–249
Israel, M. S. 112, 115
Isshiki, K. 45, 47–48, 52–53
Itkin, P. 235, 248
Ito, M. 71, 88
Itoh, O. 50, 53
Iwama, T. 70, 87–88
Iyengar, R. 316, 337
Iyer, V. N. 118, 129

Jackson, D. A. 265, 278
Jahde, E. 102, 114
Janmey, P. A. 200, 217–219, 227
Jansen, R. 274, 276, 281
Janssen, Y. 253, 262
Jansson, S. 258, 263
Jaskiewicz, J. A. 147, 148, 158, 159, 161–162
Jastorff, B. 140, 146
Jayaram, H. N. 12, 21
Jelinek, L. J. 146

Jensen, H. K. 71, 73, 85, 88–89
Jeong, K. S. 102, 106–108, 114
Jéquier, E. 163, 176
Jimenz, M. L. 245, 249
Johansson, N. G. 70, 87
John, R. 283, 291
Johnson, R. K. 270, 272–274, 280–281
Johnson, S. B. 193, 198
Johnston, D. G. 169, 177
Johnston, J. 174, 177
Johnston, P. A. 217, 227
Johtoh, N. 47, 52
Jois, M. 133, 146
Jones, B. S. 147, 157, 159, 162
Jones, D. 251, 261
Jones, D. F. 91, 100
Jones, P. 258, 262
Joseph, S. K. 133, 137, 145
Julusson, G. 70, 87
Jungas, R. L. 134, 146
Jurdic, P. 39, 41

Kabsch, W. 211, 212, 223, 226
Kaempfer, S. 163, 176
Kageyama, S. 50, 53
Kahn, C. R. 313, 336
Kahn, R. A. 283–284, 286, 289, 292
Kakeya, H. 48–49, 53
Kallinowski, F. 101–102, 110, 113, 115, 117, 127
Kallman, R. F. 119, 124, 129
Kalopissis, A.-O. 187–188, 191, 198
Kam, T. S. 51, 53
Kamen, B. 251, 261
Kamiya, T. 70, 87
Kaplan, O. 111, 115
Karlsson, A. 70, 87
Kasahari, N. 70, 88
Kasai, M. 118, 128–129
Kasper, C. B. 118, 129
Kateilah, S. M. 137, 146
Kauffman, M. G. 71, 83, 88
Kaufman, F. C. 91, 98, 100
Kawada, M. 47, 52
Kawasaki, T. 70, 87–88
Kazaki, H. 251, 260
Kaziro, Y. 303, 315, 334
Keating, M. J. 70, 87
Kedishvili, N. Y. 147–149, 151–159, 162
Kehlenbach, R. H. 289, 292
Keifer, G. 251, 261
Keller, H. 211, 226
Kelley, M. 122, 130
Kelley, W. N. 229, 242, 233–234, 237, 246–249
Kelly, T. J. 71, 73, 79, 83, 88–89
Kennedy, G. 255, 262
Kennedy, K. A. 117–119, 127–129
Kennedy, S. 255, 262
Keppler, D. 229, 247
Kerbey, A. L. 147, 157, 159, 161–162
Kervina, M. 232, 248
Kessler, S. W. 231, 248
Keyes, S. R. 117–120, 122–124, 128, 130
Kiefer, G. 251, 261
Kierdaszuk, B. 70, 87
Kikuchi, T. 118, 128
Kilberg, M. S. 132, 145
Kilgour, E. 305–306, 319–320, 334, 337
Kilkenny, M. 259, 263
Kim, J. W. 217–218, 227
Kim, M. 245, 249
Kim, S. G. 102, 114
Kim, Y. K. 71, 88
Kindsvogel, W. 146
King, C. J. 229, 233–234, 240, 247
Kinney, M. 175, 178
Kinoshita, S. 118, 129
Kipper, N. 283–284, 286, 292
Kirk, M. J. 166, 168, 177
Kit, S. 70, 88
Kita, K. 229–231, 233–236, 238–243, 247–249
Kizaki, H. 251, 261
Klatzmann, D. 71, 88
Klein, S. 170, 177
Klenzie, B. 180, 197
Kletke, S. 163, 176
Klinger, H. P. 70, 88
Kloes, M. 110, 115
Kmetz, P. 321–322, 323
Knoop, C. 110, 115
Knowler, J. T. 316, 317, 319, 337
Knowles, R. G. 132, 145
Kohalmi, S. E. 69, 86
Kohn, W. 251, 261
Kohono, K. 274, 276, 281
Koizumi, Y. 44, 52
Kojime, I. 310, 335
Komiyama, T. 118, 128
Kon, H. 118, 128
Kondrup, J. 192, 193, 198
Konno, Y. 251, 261
Korn, E. D. 214, 227
Kornberg, A. 74, 89, 229, 246
Koutcher, J. A. 102–103, 114
Kovacevic, Z. 132, 145
Kovacina, K. S. 203, 225
Koyano, T. 51, 53
Kozak, C. 70, 88

Krakoff, I. H. 55–56, 67
Kraus-Friedmann, N. 133, 145
Krebs, E. G. 203, 206, 226
Krebs, H. A. 131, 133, 145–146, 184, 197
Krieg, J. 203, 226
Kristensen, T. 71, 85, 88
Krupinski, J. 303, 304, 334
Kucherlapati, R. S. 70, 88
Kudo, H. 70, 88
Kudoh, J. 233, 235, 241, 248
Kuehl, W. M. 37, 41
Kufe, D. 36, 40
Kuijper, J. L. 146
Kuntz, M. J. 147–149, 162
Kunz, B. A. 69, 85–86, 89
Kuramochi, S. 37, 41
Kuroda, K. 210, 226
Kuroiwa, S. 50, 53
Kushnir, T. 111, 115
Kuwano, M. 274, 276, 281
Kvamme, E. 143–144, 146
Kwack, H. 106, 115
Kwiatkowski, D. J. 200, 225

Lacey, G. 118, 129
Lacey, J. H. 133, 137, 144
Laemmli, U. K. 208, 226, 266, 269, 272, 279–80
Lai, M.-H. T. 69, 87
Lai, P. 259, 263
Lakey, T. 306–307, 319, 334
Lalanne, M. 229, 247
Lalley, P. A. 70, 88
Lamb, J. 217, 219, 227
Lamb, N. J. C. 306, 335
Lambooy, L. 253–254, 262
Lands, W. E. M. 193, 198
Lane, D. 269, 280
Lane, M. D. 187, 198
Langeberg, L. K. 306, 335
Langer, R. 298, 301
Langley, K. 297, 301
Lanoue, K. F. 111, 115
Laroche, T. 272, 280
Larsen, O. A. 166, 177
Larsen, S. H. 91, 100
Lasater, L. 64, 66, 68
Lassen, N. A. 166, 177
Lassing, I. 217–218, 227
Lathe, R. 233, 248
Lauer, S. 251, 261
Lavan, B. E. 306–307, 310–315, 319, 334–336
Lavie, E. 102, 114
Lavoinne, A. 203, 226
Lawin, P. 131, 145
Lawrence, J. B. 193, 198
Lawrence, R. 118, 124, 129
Lazar, C. 229, 231, 247
Lazo, J. S. 117, 127
Leboeuf, B. 175, 178
Ledbetter, D. 70, 87
Ledley, F. D. 274, 276, 281
Lee, A. S. 71, 88
Lee, K. Y. 28, 32
Lee, L.-S. 73, 89
Lehman, T. C. 303–304, 334
Lehninger, A. L. 104, 114
Leibel, R. L. 174, 178
Leith, M. K. 118, 129
Lenzen, C. 132, 145
Leonard, B. J. 91, 100
Leopold, K. 117, 127
Leprince, D. 39, 41
Letcher, A. J. 30, 33
Leventhal, B. 251, 261
Leyte, A. 289, 292
Li, R. 39, 41
Li, Z. R. 37, 41
Lieberman, I. 229, 246
Liepnieks, J. J. 12, 21
Liliemark, J. 70, 87
Lin, A. J. 117, 128
Lin, T.-S. 56, 60–62, 67–68
Lind, S. E. 200, 225
Lindberg, U. 211, 217–218, 223, 227
Lindsley, D. 70, 88
Ling, V. 117, 128
Liotta, L. 293–294, 300
Lipman, R. 118, 128
Lips, C. 258, 262
Lipstein, B. 230, 247
Liu, L. F. 266–267, 270, 272, 279–280
Liu, X. M. 41
Liu, M.-C. 56, 60–62, 67–68
Liu, Z. 102–103, 114
Lively, D. H. 91, 100
Livesey, G. 170, 177
Livi, G. P. 321–323, 338
Livingstone, C. 315, 319, 336–337
Lobban, M. 329, 331, 338
Loh, K. Y. 51, 53
Lohman, J. A. B. 103, 114
Lok, S. 146
Look, K. Y. 1–2, 7–10, 20–21
Loomis, R. 122, 130
Lopez-Soriano, F. J. 111, 115
Lorico, A. 57, 60–61, 68
Low, S. Y. 132, 145
Lowry, M. 131, 144
Lowry, O. H. 58, 68
Lowy, I. 71, 88

Lu, J. 259, 263
Lui, M. S. 12, 21, 131, 144
Luk, G. 258, 262
Luke, M. 272, 280
Luna, E. J. 200, 225
Lund, B. 293, 300
Lund, P. 133, 146
Lunquist, F. 133, 146

Maatman, R. G. H. J. 193, 198
MacDonald, C. 319, 337
Machesky, L. M. 217–218, 227
Machicao, F. 210, 226
MacSween, J. M. 231, 248
Madwed, D. 117, 127
Maekawa, A. 259, 263
Magri, E. 210, 226
Mahoney, D. 251, 261
Maidorn, R. P. 102, 114
Majzoub, M. F. 137, 146
Makos, M. 258, 262
Malinen, T. 258, 263
Maller, J. 203, 226
Malloy, C. R. 107, 115
Man, K. C. 134, 146
Mandel, H. 251, 261
Manery, J. F. 111, 115
Manganiello, V. C. 306, 320, 334
Maniatis, T. 149, 162
Mannaerts, G. 188, 198
Mannherz, H. G. 211–212, 223, 226
Mansell, M. M. 57, 68
Manzoli, F. A. 23–25, 28–33
Manzoli, L. 24–25, 28–30, 32–33
Mao, J.-I. 266, 279
Maraldi, N. M. 23–25, 28–33, 273, 280
Marchisio, M. 30, 33
Marchmont, R. J. 319, 337
Marco de la Calle, C. 183, 197
Mariani, E. 272–273, 280
Marijnen, Y. 251, 260
Marmiroli, S. 30, 33
Marquardsen, A. 321–322, 337
Marshall, R. S. 117–118, 128
Martelli, A. M. 23–25, 28–33
Martin, Jr D. W. 229, 247
Martin, G. 134, 146
Maruta, H. 200–201, 210, 213, 215, 225, 226
Marz, R. 82, 85, 89
Maslowska, M. 175, 178
Masuda, T. 104, 107–108, 111, 114
Mateos, F. A. 245, 249
Matsuda, N. 45, 47, 50, 52–53
Matsudaira, P. T. 217, 219, 227
Matsui, M. 118, 129
Matsushima, Y. 259, 263
Mattern, M. R. 266, 270, 272–274, 279–281
Maubaum, J. 251, 261
Mauer, A. 251, 261
Maxwell, R. J. 103–104, 107, 113–114
Maybaum, J. 97, 100
Mayer, K. 55–56, 67
Mayer, S. E. 335
Mayes, J. 270, 274, 276, 280–281
Mayes, P. A. 187, 198
Mazzoni, M. 29–30, 32–33
Mazzotti, G. 23–25, 28–29, 31–32
McAlpine, P. J. 70, 88
McCabe, F. L. 274, 281
McClelland, A. 36, 40
McCormack, J. G. 139, 146, 251, 261
McCoy, C. L. 103–104, 114
McCready, V. R. 101–102, 113
McDougall, J. K. 70, 88
McGivan, J. D. 132–133, 137, 143, 145–146
McGregor, M. A. 315, 336
Mchale, M. M. 321–323, 338
McKelvey, V. J. 71, 89
McKenna, P. G. 69, 71, 86, 89
McKernan, P. A. 146
McKerns, K. W. 111, 115
McLellan, A. R. 315, 336
McLennan, P. A. 131, 145
Mead, J. A. R. 55–56, 67
Mecke, D. 132, 145
Medley, G. 70, 87
Meera Khan, P. 70, 88
Meijer, A. J. 132, 145
Meijer, L. 203, 226
Meisler, M. 70, 88
Mejer, J. 70, 87
Melki, S. A. 174, 178
Mellanby, J. 184, 197
Meltzer, P. S. 274, 281
Mendola, C. E. 50, 53
Merlevede, W. 201–203, 205–206, 217, 221–222, 225, 227
Merrill, G. F. 71, 88
Mertes, N. 131, 145
Metz, P. K. 321–323, 338
Meuth, M. 69, 71, 85, 86
Meuwissen, H. J. 69, 86
Meyer, L. J. 229, 231, 247
Meyn, R. 251, 261
Michell, R. H. 305, 334
Mihalache, O. 210, 226
Mikol, Y. 259, 263
Milani, D. 30, 33
Miller, R. H. 147, 158, 161

Milligan, G. 303–304, 310–311, 313, 315, 319, 334–337
Mills, S. D. 91, 100
Mimnaugh, E. G. 118, 129
Mine, T. 310, 335
Ming-Jer, T. 265, 278
Minkoff, M. 117, 127
Minoshima, S. 235, 248
Mirabelli, C. K. 266, 270, 273, 279–280
Miskimins, W. K. 36, 40
Mispelter, J. 110, 115
Mistry, S. C. 147, 157, 159, 162
Mitchell, J. P. 203, 225
Mitchell, R. H. 4, 21
Mitchell, T. 36, 40
Mitsumori, K. 259, 263
Miyata, T. 241, 249
Moini, M. 124, 130
Mollner, S. 316, 319, 337
Molloy, A. 255, 262
Monge, J. C. 175, 178
Monick, M. M. 39, 41
Montgomery, J. 252–253, 261–262
Montmayeur, J. P. 289, 292
Moon, K. H. 28–29, 32
Mooney, R. A. 187, 198
Moore, D. 117, 127
Moore, E. C. 55–56, 64, 66–68
Moreau, P. 193, 198
Morgan, R. 104, 107, 113
Morii, T. 45, 52
Morin, M. E. 112, 115
Morré, D. J. 193, 198
Morris, H. P. 2, 20, 104, 111, 114–115
Morris, N. J. 313–315, 336
Morton, N. E. 70, 88
Moses, M. 298, 301
Mosse, H. 11, 21
Moulder, J. E. 117, 124, 127, 130
Muchmore, J. H. 23, 31
Muhlbacher, F. 131, 137, 145
Mulay, S. 175, 178
Mulcahy, R. T. 118, 129
Muleris, M. 70, 87
Mullenders, L. H. F. 265, 276, 278
Mulligan, K. 163, 176
Munch-Petersen, B. 70, 73–79, 81–83, 85, 87–89
Munday, M. R. 147, 159, 162
Munoz, L. 251, 261
Murakami, S. 70, 88
Murphy, G. J. 141–142, 146, 308–311, 313, 316, 319, 335–337
Myers, C. E. 98, 100
Myslic, J. C. 211, 223, 227
Nagai, M. 2, 20, 91, 100, 251, 261
Naganawa, H. 13, 21, 44–46, 48–49, 52–53
Nagaoki, T. 259, 263
Nagatake, N. 236, 249
Nagatsu, T. 50, 53
Nahorski, S. R. 18, 21
Nakamura, H. 2, 11, 14, 20, 44, 46, 52, 91, 100
Nakamura, T. 47, 53
Nakano, K. 118, 129
Nakielny, S. 203, 226
Nanamuri, N. 147, 158, 159, 161
Nanaumi, N. 147, 149, 162
Natsumeda, Y. 2, 12, 20–21, 91, 100, 251, 260–261
Navon, G. 111, 115
Nawata, H. 70, 87
Neale, G. 170, 177
Neff, T.-A. M. 265–266, 273–274, 278
Negendank, W. 102, 113
Negri, C. 272–273, 280
Nelkin, B. 258–259, 262
Nelson, J. 251, 261
Nelson, W. G. 266, 279
Neri, L. M. 24–25, 28–30, 32–33, 272–273, 280
Newell, K. W. 103, 114
Newlands, C. 309, 335
Newsholme, E. A. 131, 137, 144, 146, 175, 178, 191, 198
Nickel, W. 283–284, 286, 292
Nievers, M. 29, 32
Niggli, V. 211, 226
Nikkilä, E. A. 164, 176
Nilsson, D. 239, 249
Nilsson-Ehle, P. 173, 177
Ninfa, A. J. 156, 162
Nishida, E. 210, 226
Nishioka, H. 13, 21, 45–47, 52
Nissim, I. 132, 145
Noker, P. E. 117, 127
Nonomura, S. 51, 53
Nutting, D. F. 316, 337
Nygaard, P. 70, 87

O'Callaghan, J. 259, 263
O'Hara, P. J. 146
O'Malley, B. W. 265, 278
Öberg, B. 70, 87
Ockner, R. K. 193, 198
Ogata, E. 310, 335
Ogata, J. 47, 53
Ognibene, A. 24–25, 29, 32–33, 272–273, 280
Ogreid, D. 140, 146

Ohnishi, T. 111, 115
Ohno, S. 251, 261
Ohse, T. 51, 53
Ohta, Y. 210, 226
Okamoto, R. 70, 88
Okazaki, R. 74, 89
Oki, T. 118, 128
Okunieff, P. 101–102, 110, 113, 115, 117, 127
Olah, E. 2, 12, 21, 251, 260
Oleson, J. 117, 127
Olivecrona, T. 173, 177
Olofsson, S.-O. 179, 192, 196, 198
Olsen, R. 118, 129
Ono, M. 274, 276, 281
Onoda, T. 48, 53
Onodera, H. 259, 263
Ontko, J. 184, 197
Optiz, J. M. 70, 88
Orci, I. L. 134, 139, 146
Ordidge, R. J. 103, 114
Osheroff, N. 266, 279
Oskarsson, M. 104, 106, 107, 114
Otsuka, M. 49, 53
Otsuki, T. 229–231, 233, 236, 247
Owen, T. C. 56, 58, 68

Pacitti, A. J. 137, 146
Paff, M. T. 265–266, 273–274, 278, 280
Pai, E. F. 211–212, 223, 226
Pain, B. 39, 41
Paklaka, S. 258, 263
Palade, G. E. 291–292
Palella, T. D. 235, 239, 248
Palmer, T. M. 315, 319, 336
Palotie, A. 258, 263
Pan, B. 251, 261
Pan, S.-S. 118, 128
Papa, S. 23, 31
Papac, R. J. 118, 124, 129–130
Pardee, A. B. 71, 88
Pardini, L. L. 118, 129
Pardini, R. S. 118, 129
Pardoll, D. M. 265, 273, 278
Pariza, M. W. 183, 197
Park, J. 258, 262
Park, O.-J. 147, 159, 162
Parker, E. 270, 280
Parker, P. J. 217, 227, 310–311, 313, 316, 318 319, 335, 337
Parry-Billings, M. 175, 178
Partin, A. W. 265, 278
Partridge, C. W. 70, 88
Pascale, R. 259, 263
Pasternak, C. A. 111, 115
Patel, H. 147, 158, 161
Paterson, K. R. 315, 336
Patten, R. L. 164, 176
Payne, R. 70, 88
Payrastre, B. 29, 33
Pederson, P. L. 110, 115
Peeters, B. 222, 227
Peeters, R. A. 193, 198
Pelech, S. L. 203, 226
Peltonen, L. 258, 263
Per, S. R. 266, 279
Perez, N. 297, 301
Perkin, A. G. 51, 53
Petroff, O. A. 102, 113
Pettit, F. H. 149–150, 157, 162
Pienta, K. J. 265, 278
Pilz, R. B. 229–230, 247
Pinna, G. 259, 263
Plagemann, P. G. W. 82, 85, 89
Plunkett, W. 70, 87
Pogson, C. I. 132, 145
Poiesz, B. 258, 262
Poirier, L. 259, 263
Pollara, B. 69, 86
Pollard, T. D. 200, 217–218, 225, 227
Polomski, L. 128
Pontiggia, P. 112, 115
Poore, G. A. 91, 100
Popov, K. M. 147–148, 150–152, 156–159, 161–162
Popp, D. 211, 223, 226
Potts, J. L. 166, 168, 170, 177
Pradines-Figures, A. 164, 176
Prajda, N. 1–6, 9, 11–12, 14, 20, 21, 251, 260
Preidecker, P. J. 64, 66, 68
Preusch, P. C. 118, 129
Previati, M. 29, 32
Price, D. J. 203, 226
Price, N. C. 14, 21
Prichard, J. W. 102, 113
Priestman, D. A. 147, 157, 159, 162
Pritsos, C. A. 118, 121, 125, 126, 128–130
Pryde, J. 306, 324–325, 335
Przepiorka, D. 258, 259, 262
Ptashne, K. A. 112, 115
Puchstein, C. H. 131, 145
Pugh, T. D. 183, 197
Puig, J. G. 245, 249
Pullinger, C. R. 183, 197
Puype, M. 207, 226
Pyne, N. J. 306, 311, 313, 315, 319, 321 334–337

Qian, D. 134, 146
Quaade, F. 166, 177
Quin, A. M. 208, 226

Radcliffe, A. 270, 280
Radda, G. K. 107, 115
Rader, D. J. 180, 197
Rajewsky, M. F. 102, 114
Rana, R. S. 4, 21
Randall, R. J. 58, 68
Randazzo, P. A. 289, 292
Randle, P. J. 147, 157, 159, 161, 162
Rapp, U. R. 203, 225
Rappa, G. 57, 60, 61, 68
Rasmussen, H. H. 207, 226
Rauth, A. M. 117, 118, 128
Ravel-Chapuis, P. 39, 41
Ravussin, E. 163, 176
Reardon, M. A. 2, 20
Reber, T. 70, 88
Reddy, C. D. 37, 41
Reddy, E. P. 37, 41
Reed, L. J. 149, 150, 157, 162
Regen, D. M. 174, 178
Reichard, P. 71, 89
Reid, J. S. 163, 176
Reiger, D. 213, 227
Reinhold, H. S. 101, 104, 113
Rennie, M. J. 131–132, 145
Renold, A. E. 175, 178
Rettich, D. 132, 145
Rhee, J. G. 102–103, 114
Rhee, S. G. 28–30, 32–33, 217–218, 227
Rhyu, S. H. 28, 32
Ricci, B. 180, 197
Rice, G. C. 117, 128
Richardson, L. J. 147, 157, 159, 161
Rider, M. 207, 226
Riley, G. A. 221, 227
Risse, G. 200–201, 210, 213, 225
Rizzo, M. T. 1–2, 4–6, 20, 46, 52
Rizzoli, R. 23–24, 28, 31–32
Roach, P. J. 203, 225
Robberecht, P. 311, 335
Roberts, M. F. 239, 249
Roberts, P. M. 36, 40
Robertson, L. E. 70, 87
Robin, E. D. 112, 115
Robinson, M. J. 266, 279
Robotham, E. 118, 129
Robson, C. N. 118, 129
Rockwell, S. 117–120, 123–124, 127–130
Roderick, T. H. 70, 88
Rodrigues, L. M. 102, 106–108, 113–115
Roeske, R. W. 203, 225
Roessler, B. J. 235, 239, 248
Roheim, P. S. 187, 198
Ronen, S. M. 110, 115
Roos, D. 251, 260
Rose, P. A. 71, 88
Rose, S. E. 91, 95, 98, 100
Rosenberg, A. H. 72, 89
Rosenberg, G. B. 146
Rosenberg, S. 293, 300
Rosebrough, N. J. 58, 68
Rosenthal, S. M. 111, 115
Ross, D. G. 118, 129, 229, 233, 242, 247, 249
Roth, E. 131, 137, 145
Roth, R. A. 203, 225
Rothenberg, P. L. 313, 336
Rothman, J. E. 283, 291
Rotin, D. 102–103, 113
Rozengurt, E. 229, 247
Rozycki, M. D. 211, 223, 227
Ruano, A. R. 5, 21
Rubbini, S. 25, 29, 32–33
Rubinstein, P. 70, 88
Ruddle, F. 36, 40
Ruddle F. H. 70, 88
Ruggui, M. 259, 263
Rulka, C. 289, 292
Runkel, S. 110, 115
Rusiñol, A. 180, 193, 197–198
Russo, S. A. 85, 89
Rustaeus, S. 179, 196
Ruutu, T. 258, 263
Ryu, S. H. 28–29, 32
Rockwell, S. 119, 124, 129, 130

Sacchi, N. 36, 40
Sadee, W. 97, 100
Sagara, T. 70, 88
Sakai, H. 210, 226
Sakakibara, Y. 245, 249
Sakamoto, K. 4–5, 18, 21
Sakamoto, S. 70, 87–88
Sakiyama, F. 207, 226
Sala. C. 272, 280
Salandt, D. Y. 111, 115
Salter, M. 132, 145
Samarut, J. 39, 41
Sambrook, J. 149, 162
Sanfilippo, O. 251, 261
Santi, P. 23, 31
Santi, S. 272–273, 280
Sariban, E. 36, 40
Sartorelli, A. C. 55–56, 60–62, 64, 66–68, 117–118, 123–124, 127–130, 252, 262
Sasaguri, T. 47, 53
Sasaki, C. T. 118, 124, 129
Sasaki, Y. 44, 48, 52–53
Sasvari-Székely, M. 70, 88
Sathe, G. M. 321–323, 338
Sato, A. 64, 66, 68
Satta, G. 259, 263
Saucan, L. 291, 292

Saville, M. 306, 334
Sawa, R. 46, 52
Sawa, T. 13, 21, 44–49, 52–53
Schabel, Jr, F. 253, 262
Schaddix, S. C. 55, 56, 67
Scheer, U. 272, 273, 280
Scheller, R. H. 283, 291
Schiffer, L. M. 104, 114
Schimke, R. T. 117, 128
Schleicher, M. 213, 217–218, 227
Schlenger, K. H. 110, 115
Schmid, H. H. O. 193, 198
Schmid, P. C. 193, 198
Schmidt, C. A. 267, 269, 276, 279–280
Schmidt, G. 57, 68
Schnebli, H. 253, 262
Schneider, Y.-J. 91, 100
Schreckenbach, T. 200–201, 210, 213, 225
Schreiber, G. 102, 114
Schubert, K. R. 229, 247
Schultz, F. 174, 177
Schumaker, V. N. 180, 197
Schutt, C. E. 211, 223, 227
Schutz, Y. 163, 176
Schweiger, A. 210, 226
Scott, J. D. 255, 262, 306, 335
Scow, R. O. 173, 174, 177
Sebolt, J. 131, 144
Seddaiu, M. 259, 263
Seegmiller, J. E. 69, 84, 235, 248
Sefton, B. M. 210, 226
Seino, S. 235, 239, 248
Sekizawa, R. 47, 52
Sen, R. 36, 41
Senekowitsch, C. 118, 129
Sequenza, M. 259, 263
Sergent-Engelen, T. 91, 100
Setta, G. 259, 263
Seyedsadr, M. 102, 114
Shackelton, C. H. L. 147, 159, 162–163, 176
Shaddix, S. C. 55, 56, 67
Shadid, S. 166, 169, 171–173, 177
Shakur, Y. 306, 321–322, 324–325, 329, 335, 337–338
Shamsuddin, A. M. 4, 5, 18, 21
Shansky, C. W. 117, 128
Share, L. 316, 337
Sharkis, J. 258, 262
Sharp, D. 180, 197
Sharp, P. A. 36, 41
Shaw, D. 101–102, 113
Shaw, M. 70, 88
Shelton, E. 229, 233, 242, 247
Shen-Ong, G. L. C. 39, 41
Sheperd, J. 296, 301
Sheppard, P. O. 146
Sherley, J. L. 71, 73, 79, 88–89
Shibayama, T. 200–201, 210, 213, 225
Shibuya, M. 47, 52
Shigesada, K. 229, 246
Shimada, H. 233, 235–236, 239, 241, 248–249, 297, 301
Shimada, N. 50, 53
Shimizu, M. 118, 129
Shimizu, N. 233, 235, 241, 248
Shimizu, S. 184, 197
Shimizu, Y. 235, 248
Shimokado, K. 47, 53
Shimomura, Y. 147–149, 151–152, 156, 158–159, 161–162
Shimura, N 46, 47, 52
Shows, T. B. 70, 88
Shulman, R. G. 102, 113
Shuster, J. 251, 261
Shyy, S. 266, 279
Sibley, D. 307, 310–311, 334
Sie, K. L. 270, 280
Siegel, D. 118, 129
Siemann, D. W. 117, 127
Sies, H. 131, 144, 229, 247
Silberman, L. 270, 280
Silverman, A. 258, 262
Simic, M. G. 118, 129
Simile, M. 259, 263
Simizu, S. 47, 53
Simmonds, H. A. 245, 249
Simms, E. S. 229, 246
Simpson-Herren, L. 117, 127
Singh, H. 36, 41
Singhal, R. L. 1–10, 12, 14, 20–21, 69, 86
Sinha, B. K. 98, 100, 118, 129
Sjöberg, A. 192, 198
Skipper, H. 253, 262
Skoda, J. 259, 263
Slade, D. L. 274, 281
Sladek, S. 261
Slagel, V. 70, 87
Slate, D. L. 91, 100
Sledge, Jr G. W. 1–2, 7–10, 20
Sligar, S. G. 118, 128
Small, M. 315, 336
Smets, L. A. 102, 114
Smith, C. D. 23, 24, 32
Smith, C. J. 306, 320, 334
Smith, D. B. 200, 225
Smith, E. M. 132, 145
Smith, L. C. 174, 177
Smith, M. L. 229, 247
Smith, R. A. 146
Smith-Nanni, C. 265, 266, 273, 274, 278
Sniderman, A. D. 175, 178
Snoeck, G. T. 29, 33
Soboll, S. 132, 145

Sogin, D. C. 237, 249
Sokoloski, J. 252, 262
Söling, H. D. 283–284, 286, 292
Söllner, T. 283, 291
Solomon, E. 70, 87
Son, Y. H. 118, 124, 129–130
Song, C. W. 102–103, 114
Sonobe, S. 210, 226
Sonoda, T. 230, 235–236, 239–243, 248–249
Sostman, H. D. 117, 127
Souba, W. W. 131, 137, 144, 146
Southwick, F. S. 200, 225
Sparks, C. E. 179, 187, 197
Sparks, J. D. 179, 187, 197
Spasokukotskaja, T. 70, 87–88
Spencer, T. L. 104, 114
Sperling, O. 230, 247
Spiegel, A. M. 311, 315, 319, 336
Spranger, J. W. 70, 88
Sprecher, C. A. , 146
Spring, D. J. 180, 197
Squarzoni, S. 23, 31
Squires, E. J. 131, 144
St-Luce, S. 175, 178
Staal, S. 258, 262
Stalmans, W. 221, 227
Staub, M. 70, 88
Steebergh, P. 258, 262
Steen, R. G. 107, 115
Steeper, J. R. 57, 68
Stehelin, D. 39, 41
Stehle, P. 131, 145
Stehman, F. B. 2, 21
Stein, O. 187, 198
Stein, Y. 187, 198
Stepp, L. R. 149–150, 157, 162
Sternglanz, R. 266, 279
Stet, E. 252–255, 261–262
Stetler-Stevenson, W. 293, 294, 300
Steuart, C. E. 57, 68
Stevens, A. N. 101–102, 113
Stevens, L. 14, 21
Stewart, C. J. 71, 88
Stinski, M. F. 39, 41
Stinson, K. K. 66, 68
Stock, A. M. 162
Stock, J. B. 156, 162
Stohrer, M. 110, 115
Stossel, T. P. 200, 217–218, 225, 227
Stoward, P. J. 112, 115
Strålfors, P. 165, 174, 177
Strassheim, D. 315, 317, 319, 336
Stratford, I. 103, 114
Struck, R. 252, 261
Stubbs, M. 2, 20, 102–104, 106–108, 113–115
Studier, F. W. 72, 89
Suck, D. 211–212, 223, 226
Sudhalter, J. 298, 301
Südhof, T. C. 217, 227
Sugata, D. 47, 52–53
Sugden, M. C. 147, 159, 162
Sugiura, Y. 118, 128
Suh, H. W. 28–29, 32
Suh, P. G. 28–29, 32
Sujikai, I. 47–48, 52
Sullivan, M. 321–323, 337
Sun, H.-W. 217, 227
Suttle, D. P. 267, 269, 274, 276, 279, 281
Sutton, G. P. 2, 21
Suzuki, K. 251, 261
Suzuki, M. 147, 158–159, 161–162
Svoboda, M. 311, 335
Sweeney, M. J. 91, 95, 100
Swinnen, J. V. 306, 321, 334
Switzer, R. L. 229, 233–234, 237, 239–240, 247–249
Szabalski, W. 118, 129
Szekeres, T. 69, 91, 86, 100
Szondy, S. 2, 20
Szweda, L. I. 134, 146
Szwergold, B. S. 18, 21

Taberner, N. 315, 336
Tabor, H. 111, 115
Taira, M. 230, 233–235, 239, 241, 248
Tajima, H. 47, 52
Takahashi, S. 200, 210, 213, 225–226
Takahashi, T. 118, 129
Takahashi, Y. 44–45, 49, 52–53
Takano, H. 274, 276, 281
Takeda, E. 251, 260
Takeuchi, T. 13, 21, 44–50, 52–53
Tan, C. 55–56, 67
Tan, K. B. 266, 274, 279, 281
Tanaka, K. 47, 52
Tanaka, S. 47, 53
Tang, E. Y. 310, 316, 318–319, 335, 337
Tani, Y. 184, 197
Taniguchi, Y. 45, 52
Tannock, I. F. 102–103, 113–114, 117, 127
Taskinen, M.-R. 164, 176
Tastenoy, M. 311, 335
Tatibana, M. 229–231, 233–236, 239–243, 246–248
Tatsuta, K. 48, 53
Tattersall, M. H. N. 85, 89
Tawara, J. 47, 52
Taylor, S. 297, 301
Taylor, D. P. 321–323, 338

Taylor, K. A. 118, 129
Taylor, S. S. 140, 146
Teicher, B. A. 117, 127
Thannhauser, S. J. 57, 68
Thelander, L. 64, 66, 68, 71, 89
Thomas, C. 258, 259, 262
Thomas, G. 203, 226
Thomas, H. 253, 262
Thomas, J. 188, 198
Thomas, M. H. 28, 32
Thompson, B. 37, 41
Thor, K. 102, 114
Thorlin, T. 192, 198
Tildon, J. T. 131, 144
Tobin, J. 166, 177
Todokoro, K. 37, 41
Toftness, B. R. 55–56, 67
Tomasz, M. 118, 128
Tomchick, R. 55–56, 67
Tonks, N. K. 203, 225
Törcsvari, V. 70, 88
Tornqvist, H. 165, 174, 177
Torphy, T. J. 321–323, 338
Townsend, A. J. 99, 100
Tozer, G. M. 104, 107, 113
Tozzi, M. 251, 261
Traina-Dorge, V. 70, 87
Traver, R. D. 118, 129
Trax, P. A. 182, 197
Trent, J. M. 274, 281
Tressler, R. J. 91, 100
Trijbels, J. 253–254, 262
Trinder, P. 182, 197
Tritton, T. R. 121, 130
Trivedi, D. 309, 311, 335
Trueworthy, R. 253–254, 262
Trush, M. A. 118, 129
Tsiftsoglou, A. S. 64, 66, 68
Tsuji, T. 47, 52
Tsukada, K. 70, 87–88
Tsukitani, Y. 140, 146
Tubo, R. A. 265, 276, 279, 281
Tucker, H. N. 175, 178
Tulpule, A. 98, 100
Turck, C. W. 180, 197
Turluck, D. A. 91, 95, 98, 100
Turner, R. W. 91, 100
Turner, W. B. 91, 100
Tygstrup, N. 133, 146
Tyrsted, G. 70–71, 73–79, 81–83, 85, 87–89
Tzeng, D. 251, 260

Uchida, T. 47, 52
Uchida, Y. 274, 276, 281
Ui, H. 47, 48, 52
Ullman, B. 239, 249
Umezawa, H. 47, 52
Umezawa, K. 13, 21, 44–43
Unger, R. H. 134, 139, 146
Unson, C. G. 311, 315, 319, 336
Urano, M. 102–103, 114
Utsunomiya, J. 70, 87
Uzu, K. 118, 129

Valmori, A. 272–273, 280
Van Baal, J. 252–253, 261
Van Bergen en Henegouwen, P. M. P. 29, 32
Van Damme, J. 207, 226
Van der Weyden, M. B. 70, 73, 87, 89
Van Gennip, A. 251, 260
Van Harken, D. R. 184, 197
Van Hoof, C. 221–222, 227
Van Laarhoven, J. 251, 261
Van Mourik, J. H. G. 29, 33
Vance, D. E. 180, 193, 198
Vance, J. E. 180, 193, 197, 198
Vande Linde, A. M. Q. 107, 115
Vandekerckhove, J. 200–204, 206, 211, 213–214, 218–220, 222, 225–227
Vannier, C. 164, 176
Vannini, M. 259, 263
Vaughan, L. A. 91, 98, 100
Vaughn, J. P. 265, 276, 278
Vaupel, P. 101–102, 110, 113, 115, 117, 127
Veech, R. L. 102, 106–108, 111, 114–115
Veerkamp, J. H. 193, 198
Veloso, D. 104, 106–107, 114
Venturelli, D. 39, 41
Verkade, H. 180, 197
Verkleij, A. J. 29, 32
Vertine, P. 258, 262
Verweij, J. 293, 300
Vesely, J. 259, 263
Vickers, P. J. 99, 100
Vinay, P. 131, 144
Vincent, N. 134, 146
Vinci, M. 259, 263
Vinnars, E. 131, 137, 145
Voelkel, K. 266, 279
Vogels-Mentink, T. 253–254, 262
Vogelstein, B. 258, 262, 265, 273, 278
Vogt, M. 253, 262
Volk, A. 110, 115
Volk, T. 102, 114
Von der Decken, A. 131, 145
Von Sonntag, C. 118, 129
Vorhees, W. D. 102, 114
Vu, H. 175, 178
Vucenik, I. 4–5, 18, 21

Vulliet, P. R. 203, 225
Vyas, D. M. 122, 130

Waelkens, E. 200–204, 206, 211, 213–214, 218–222, 225, 227
Wager-Smith, K. 180, 197
Wainfan, E. 259, 263
Wakelam, M. J. O. 141–142, 146, 309, 311, 335–336
Walker, K. M. 146
Wallace, A. V. 307, 320, 335, 337
Wallace, K. 296, 301
Walsh, M. 175, 178
Walter, J. B. 112, 115
Wang, A. 203, 225
Wang, J. C. 102, 106–108, 114, 266, 279
Wang, J. W. J. 47, 52
Wang, L. 70, 87
Wang, L. G. 37, 41
Wang, X. 297, 301
Wang, Y. 56, 60, 68
Warburg, O. 101, 113
Ward, B. 296, 301
Ward, J. F. 118, 129
Warmoth, M. R. 276, 281
Wasylyk, B. 38, 41
Watanabe, T. 49, 53
Watanabe, Y. 50, 53
Watford, M. 131–133, 139, 145
Watson, P. A. 303–304, 334
Watson, R. J. 37, 40
Watt, P. 203, 226
Watters, J. M. 138, 146
Weber, G. 1–2, 4–12, 14, 20–21, 24–25, 32, 46, 52, 69, 86–87, 91, 100, 104, 110, 114–115, 131, 144, 229, 247, 251, 260–261
Weher, J.-M. 170, 177
Wei, C. 51, 53
Weiner, I. M. 229, 246, 247
Weinshilhoum, R. 261
Weinstein, Y. 229, 247
Weir, D. 255, 262
Weiss, K. 70, 88
Weissberg, J. B. 118, 124, 129
Welch, K. M. A. 107, 115
Wells, W. W. 23–24, 32
Wernermann, J. 131, 145
Wetterau, J. R. 180, 197
Wetterman, J. R. 180
Wettesten, M. 179, 192, 196, 198
Whiteheart, S. W. 283, 291
Whitesell, R. R. 174, 179
Whyte, P. L. 165, 177
Wieland, O. H. 210, 226
Wiggins, D. 189, 198
Wike-Hooley, J. L. 101, 104, 113
Wikiel, H. 35, 40
Wiklund, O. 192, 198
Wilkie, D. R. 101–102, 113
Wilkinson, D. S. 57, 68
Wilkinson, Y. A. 69, 71, 86, 89
Willecke, K. 70, 88
Willett, B. 319, 337
Williams, R. H. 91, 100
Williams, S. S. 11, 21
Williamson, D. H. 165, 177, 184, 197
Williamson, J. R. 111, 115
Willis, R. C. 229, 230, 247
Wilmore, D. W. 138, 146
Wilson, A. 315, 336
Wilson, D. F. 110, 115
Wilson, J. M. 233, 234, 248
Wilson, M. 321, 337
Wilson, S. R. 313, 320, 336–337
Wiltshaw, E. 101–102, 113
Wirtz, K. W. A. 29, 32–33
Woessner, R. D. 273, 280
Wolf, C. R. 118, 129
Wolfe, R. R. 170, 177
Wong, H. 122, 130
Wood, P. 103, 114
Woodgett, J. R. 203, 225
Woods, R. 253, 262
Wossner, R. D. 270, 280
Wright, D. S. 91, 95, 98, 100
Wright, J. D. 193, 198
Wu, H.-Y. 266, 279
Wu, J. 258, 262
Wu, K. 147, 159, 162, 163, 176

Xu, S. P. 56, 68

Yalowich, J. C. 267, 274, 280
Yamada, H. 184, 197
Yamada, K. 230, 233–235, 239, 241, 248–249
Yamaji, Y. 251, 261
Yamamoto, M. 184, 197
Yamamoto, T. 51, 53
Yamashita, K. 47, 52–53
Yanagisawa, H. 37, 41
Yang, L. Y. 70, 87
Yang, Y. C. 289, 292
Yao, Z. 193, 198
Yasunaga, T. 241, 249
Yeaman, S. J. 147, 149, 150, 157, 159, 162
Yeh, A. K. 232, 248
Yeh, Y. A. 1–6, 9, 10, 20–21, 69, 86

Yen, R. C. K. 235, 248
Yin, H. L. 200, 217, 225, 227
Yip, L. C. 232, 248
Yokota, T. 47, 53
Yonezawa, K. 203, 225
Yoshimura, M. 316, 337
Yu, F.-X. 217, 227
Yudkoff, M. 132, 145

Zammit, V. A. 191, 198
Zander, J. 131, 145
Zaner, K. S. 200, 225
Zed, C. 170, 177
Zhao, L. 35, 40
Zhao, Y. 147–149, 151–154, 156–159, 161–162
Zhu, L. Y. 56, 68
Ziegler, B. 132, 145
Zielke, H. R. 131, 144
Zigmond, S. H. 212, 227
Zini, N. 23, 31, 272, 273, 280
Zwaagstra, J. C. 303–304, 334
Zwelling, L. A. 270, 275–276, 280–281

SUBJECT INDEX

N-Acetylated-aminopyridine-2-carboxaldehyde thiosemicarbazones
  effects on
    CDP reductase 59, 61
    L1210 cell growth 59, 61
    mice bearing L1210 cells 61, 62
  structures 62
Actin
  binding proteins, classification 200
  capping 214–216, 220
  dephosphorylation by protein phosphatases 220–223
  fragmin binding 215–217
  nucleation 214
  phosphorylation 200, 201
    by AFK 204, 211
  threonine sites 202, 212, 223
  polymerization
  control 199, 200
  neomycin inhibition 218
  profilin complex 218
  structure 212
F-Actin filament capping by actin-fragmin complex 214–216
G-Actin polymerization to F-actin 199
Actin-fragmin complex
  as substrate for AFK 203, 224
  binding to PIP_2 218, 219
  capping activity, PIP_2 on 220, 224
  nucleating activity
    inhibition 214
    PIP_2 on 219, 220
  phosphorylated
    dephosphorylation of 220–223
    physiological activities 215, 216
  physiological activities 213, 214
  resistance to PIP_2 dissociation 218
Actin-fragmin kinase (AFK)
  action 200
  comparison with other actin kinases 210, 211
  independent behavior 223
  inhibition by DNase I 205, 212
  modulation by various effectors 206, 207
  molecular mass 201, 202
    80K identification 208–210, 223
    78K second component 202, 209, 210
  possible identity with Cap 42(a+b) kinase 210, 213
  primary structure partial sequence analysis 207, 208
  proteolytic peptides from 209
  purification 201
  sequential phosphorylation of actin 211
  substrate
    recognition by fragmin 204, 205
    specificity 202–204, 206, 223
Actin kinases, comparison with AFK 210, 211
Adenosine deaminase (EC 3.5.4.4)
  deficiency leading to immune deficiency 69
Adenosine kinase (AK, EC 2.7.1.20)
  phosphorylation of me-MPR 253
S-Adenosyl-L-homocysteine (SAH)
  increase on
  me-MPR treatment of cells 255–257
  6MP treatment of cells 255–257
S-Adenosylhomocysteine hydrolase (SAHH, EC 3.3.1.1)
  activity in presence of 6MP and metabolites 255
  in transmethylation pathway 257
S-Adenosyl-L-methionine (SAM)
  chemopreventive effects 259, 260
  dependence of TPMT 252
  depletion by cell treatment with me-MPR or 6MP 255–259
  in transmethylation pathway 257
Adenylate cyclase (EC 4.6.1.1)
  activity, control of 303–305
    by glucagon receptor 311
    desensitization 307–310
    G_i,G_s balance 311, 312
    in diabetes 315–319
    inhibition by G_i 317
    inhibition by insulin 313
  isoforms 304
  receptors coupling to G-proteins 304, 305, 315
Adipocytes
  LPL synthesis in 164
  possible uptake of MAG 174
Alkaline phosphodiesterase in hepatocyte secretory vesicles 284, 286

Amino-substituted
pyridine-2-carboxaldehyde
thiosemicarbazones
effects on
CDP reductase 58, 60
role of iron 63–66
DNA synthesis 62–64
L1210 cell growth 58, 60
mice bearing L1210 leukemia 58–61
potential for clinical chemotherapy 66, 67
structures 59
Ammonia activation of glutaminase 132, 140
cAMP
compartmentalization within cell 306
production
glucagon stimulation 307, 308, 311
hormonal stimulation signatures 303, 304
IBMX on 308
regulation 307, 309, 310
PDEs control of 319–321, 333
signalling system 305, 309, 333
cAMP phosphodiesterase (PDE, EC 3.1.4.17)
activity
IBMX inhibitors 306
in hepatocytes 307, 309
isoforms characteristics 319, 320
membrane-binding peptide 320, 321
splice variants 320
multigene family 306
selective inhibitors 306
therapeutic potential 333
degradative system 305
type IVA human
h61 properties 321
rolipram inhibition 322, 323
splice variants 321
structure 321
type IVA and IVB in brain
distribution in different regions 329–333
enzyme species 329
rolipram inhibition 331
significance of membrane association 331, 332
type IVA rat RD1 323
hydrolysis of whole and truncated forms 327
membrane targets domain 324
solubilities of whole and truncated forms 325, 326
splice variants comparison 325
structure of 25 amino acid N-terminal domain 326, 327
thermostabilities of whole and truncated forms 327, 328
truncated species met^{26} 324–328
Amsacrine *see* mAMSA
Angiotensin converting enzyme (ACE, EC 3.4.15.1) resistance to batimastat 295
Apoprotein B (apoB)
attachment with endoplasmic reticulum layer 181
measurement 182
role in VLDL particle 179, 180
secretion, effect of TAG concentration 186
ara-C phosphorylation by dCK 70
ara-T phosphorylation by TK2 70
ATP
content of liver and hepatoma 108
hydrolysis in liver and hepatoma 109
on TK1
apparent stabilization 74, 75
effect of enzyme concentration 77
induced tetramerization 79, 80, 85
kinetic constants 79
molecular weight 74
reversibility 76, 85
AZT differential phsophorylation by TK1 and TK2 70, 71

Bacterial histidine-protein kinases
kinase domains 156
relation to mitochondrial PKs 160
Batimastat (BB-94), synthetic matrix metalloproteinase inhibitor
clinical trial 298, 300
inhibition of
B16 lung colonization and tumor growth 295–297
human colon carcinoma growth and metastasis 296, 297
human ovarian carcinoma ascites growth 296, 297
inhibitory profile 295
structure 294
Bicarbonate concentration in liver and hepatoma 106
Brain type IV PDEs
distribution within different regions 329–333
enzyme species 329
Branched chain amino acids conservation during protein deficiency 160
Branched chain α-ketoacid dehydrogenase (EC 1.2.4.1 + EC no no. + EC 1.8.1.4)
binding of kinase 158, 160
inactivation, enzymes for 147

Branched chain α-ketoacid dehydrogenase kinase (BCKDK, EC 2.7.1.115)
conserved sequence primer 150
protein malnutrition on binding 158–160
protein sequence alignment with PDK p48 subunit 150–152
purification 149
stable activity changes 147
Brefeldin A detachment of VAPP14 from membrane 288, 291

III-121C alkaloid *ras* protein inhibitor
isolation 51
structure 50
c-ets-1 protein in ML-1 cells 35, 39, 40
as transcription factor 38
c-myb expression in ML-1 cells 35, 40
intron I X-X fragment 38
regulation
by c-ets-1 protein 38
involvement of intron I 37
Ca^{2+}
accumulation in tumors 111–113
concentrations in liver and hepatoma 107, 111, 112
dependence of
fragmin activities 213
phosphorylated actin-fragmin complex 215
inhibition of AFX 206, 207
Cancer
chemotherapy *see* Chemotherapy
models of proteinase action and inhibition in progression 299
spread 293
Cap 42(a+b) protein
identity with AFK 210
induction of actin polymerization 200
phosphorylation 201
Carbamoyl-phosphate synthetase I (EC 6.3.4.16) in urea cycle 132
CDP-DG:inositol transferase inhibitors
structure 44
CDP reductase
activity assay 57
inhibition by
acetylated HCTs 59, 61
3 and 5 substituted HCTs 59, 61
CdR kinase *see* Deoxycytidine kinase
Chemotherapy
antimetabolite 251
cytokinase 294
glutamine analogs 131
matrix metalloproteinase inhibitors 294–300
clinical trial 298, 300
mitomycin C, X-irradiation combination 118, 127
6MP, MPA synergism 253
6MP on tumor progression 259, 260
nitrogen mustard 293
porfiromycin, X-irradiation clinical trials 124, 127
possible alteration to tumor pH_i and pH_e 102, 103
problems in hypoxic tumor cells 117, 126
resistance of colorectal tumors 99
topoisomerase II-active drugs 266, 273, 277
topoisomerase inhibitors 293
Chloroquin
on fatty acid/TAG cycling 190, 191
on VLDL TAG secretion 188, 189
Cl^- concentrations in liver and hepatoma 106
Collagenase (EC 3.4.24.7) inhibition by batimastat 295
Colorectal cancer drug design 99
Compactin inhibition of *ras* function 50
Conophylline identity with III-121C alkaloid 51
Cycloheximide on PI and PIP kinase activities 11, 14, 19
Cystathionine synthase in transmethylation pathway 257
Cytoskeletal filament classes 199
Cytoskeleton structure 200
Cytosol [^{3}H]TAG labeled 183
conversion to membrane phospholipid 195

DAG *see* Diacylglycerol
Damnacanthal
on *ras* function 51
structure 50
Deoxycytidine kinase (dCK, EC 2.7.1.74)
substrate diversity 70
$t_{1/2}$ by cycloheximide or tiazofurin 14
Dephostatin, tyrosine phosphatase inhibitor, properties and structure 49
Desferal on CDP reductase inhibition by HCTs 64, 65
DFDC (2′,2′-difluorodeoxycytidine, Gemcitabin) phosphorylation by dCK 70
Diabetes
adenylate cyclase activity in 315–319
glutaminase stimulation 139, 140
on glutaminase levels 133, 139
PDK activity and 159–161
PKC expression in 318

Diacyglycerol (DAG) decrease during differentiation 25, 26, 29
Diacylglycerol acyltransferase (DGAT, EC 2.3.1.20) activity in ER membranes 192, 193
Differentiation factors in ML-cells 35–40
Dihydrofolate reductase (DHFR, EC 1.5.1.3) chromosome location 70
2,3-Dihydroxybenzaldehyde
  inhibition of PI kinases 47
  structure 46
Dimethylsulfoxide (DMSO) differentiation of Friend cells 24
  effect on nuclear PLC activity 25–27
Dipalmitoylphosphatidylcholine (DPPC)
  [^{14}C] prelabeling of cells 182, 194
  incorporation into VLDL TAG 194
DNA
  methylation
    abnormal patterns in malignancy 258
    reduction by 6MP or me-MPR cell treatment 258
    SAM chemopreventive effect 259, 260
  replication, nuclear matrix model 265, 266
  synthesis in L1210 cells 3 and 5 substituted HCTs on 62–64
  topoisomerase II isozymes bound to 266, 270–274
DNA topoisomerase II (EC 5.99.1.3)
  -active drugs 274
  activity assay 270
  -DNA complexes
    replication model 266
    stabilization by VM-26 270, 271, 278
    subcellular distribution 271–274, 277
  isozymes
    identification 266, 269
    immunodetection 269–272
    in CEM cells 270, 271
    in matrix and non-matrix nuclear fractions 272, 273, 277
    IIα depletion in matrix of resistance cells 274–276
    IIβ localization in non-matrix fraction 273
  separation of free and bound 268
cDNA cloning of PRPP synthetase subunits 232, 233, 245, 246
DNase 1 inhibition of AFK 205, 212, 213, 223
Drug resistance
  in CEM cells 274
  multidrug resistance
    at-MDR phenotype 274
    mechanisms 265, 277

Echiguanines, PI 4-kinase inhibitors
  inhibitory properties 47
  structures 46
Endoplasmic reticulum (ER)
  fatty acid transfer into 193
  role in TAG assembly 180, 181, 187, 192
  sites of TAG synthesis 192
  TAG reesterification in 187
Endosomal markers from hepatocytes in equilibrium density gradient 284, 287
Endothelin converting enzyme (ECE) resistance to batimastat 295
Endotoxemia
  E. coli lipopolysaccharide induction of 134
  glutaminase activation in 137, 138
Epipodophylotoxins resistant cells of at-MDR phenotype 277
Erbstatin
  structure 48
  tyrosine kinase inhibitory properties 47
Escherichia coli
  expression of rat PRS I and II 236, 246
  PRPP synthetase amino acid sequence 234
Etoposide *see* VP-16

Fat deposition and mobilization, enzymes for 163, 164
Fatty acids
  esterification 164
    insulin on 174, 175
  movements in white adipose tissue 167, 173, 174
  reesterification 166
    dependence on nutritional state 169, 170
    post-prandial 171
  source of VLDL TAG 184–187, 192, 194, 196
  /TAG cycling, effects of drugs 189–191
  transfer across ER membrane 193–196
Fludarabine phosphorylation by dCK 70
Fragmin, actin binding protein
  2 actins binding 215–217
  Ca^{2+}-dependent activity 213
  gelsolin sequence homology 204
  in substrate recognition by AFK 204, 205
  properties 200, 213

G-proteins
  expression in diabetes 316, 319
  in cAMP signalling 303–305

insulin regulation 319
G_i
inhibition of adenylate cyclase 317
phosphorylation in diabetes 315, 316
G_i-2
phosphopeptide analyses 313, 314
phosphorylation in diabetes 316–318
phosphorylation sites 314, 315
signalling modulation 311
phosphorylation-dephosphorylation cycle 312
G_s complex formation with glucagon receptor 307–309
uncoupling 310
Gelatinase 72kDa (EC 3.4.24.24) inhibition by batimastat 295
Gelatinase 92kDa (EC 3.4.24.35) inhibition by batimastat 295
Glucagon
activation of glutaminase 133, 134, 140–144
activation of PKC 310–313
analog, desensitization by 311
desensitization of adenylate cyclase 307, 308
elevation in endotoxemia 138
receptor coupled signalling systems 309
receptor phosphorylation 311
receptors 142, 143
stimulation of cAMP production 307
β-Glucuronidase action on MPAG 93, 96
Glutaminase (EC 3.5.1.2)
activation by ammonia 132
diabetes on 133
hepatic, activation
by glucagon 133, 134, 140–144
by okadaic acid 140–144
by protein ingestion 134–137, 144
by Sp-cAMPS 140–144
by various agents 143
in diabetes mellitus 139, 144
in endotoxin-treated rats 137, 138, 144
intracellular signalling 139–144
hormones on 133, 138, 139
in urea cycle 132
isozymes distribution 131, 132
mitochondrial location 132
protein ingestion on 133
Glutamine
hepatic catabolism control 132
metabolic functions 131
Glutamine synthetase (EC 6.3.1.2)
in hepatocytes 132
in synthesis of glutamine 131
Glycerol blood levels before and after mixed meal 168, 171
Glycogenolysis and glucagon 141–143
Rp-8-Br-cAMPS 141–143
Sp-cAMPS 141, 142
Glycolysis in tumors 110, 111
GMP reductase (EC 1.6.6.8) $t_{1/2}$ by cycloheximide or tiazofurin 14
GMP synthetase (GAMPS, EC 6.3.4.1) in thiopurine metabolism 251, 252
Golgi *see also* Trans-Golgi network (TGN)
coat protein in equilibrium density gradient 284, 287
vesicular transport between 283
Growth factors in ML-1 cells 35–40
GTP
HPLC analysis 93, 95
inhibition by MPA 94, 95, 97, 98
synthesis by cells 93
GTP-binding protein ARF in vesicles 284, 289, 291
in density gradient 288
GTP-γ-S on vesicle budding process 289, 290
Guanine phosphoribosyltransferase (GPRT, EC 2.4.2.8) $t_{1/2}$ by cycloheximide or tiazofurin 14

H^+ (*see also* pH) gradient in liver and hepatoma 109, 110, 113
Heparin release of LPL 164
Heparin sulfate in TGN 284
Heparinase 2 treatment of sulfated proteoglycans 284
Hepatocytes
adenylate cyclase regulation 318
cAMP levels, glucagon on 307, 308
α-G_i phosphopeptide analyses 313, 314
glutaminase in 132
insulin treatment 313
mitochondria prepared from 139
PDEs mapping 319–321
phosphorylation-dephosphorylation cycle 312
PKC activation by glucagon 310, 312
signalling systems 309
α-(N)-Heterocyclic carboxaldehyde thiosemicarbazones (HCTs)
inhibition of ribonucleotide reductase 55
role of iron 63–66
Hexokinase (EC 2.7.1.1) in rapidly growing tumors 110
β-Hexosamidase in hepatocyte secretory vesicles 284, 286, 287
Histidine protein kinases 149, 150

Histidine H1 substrate for AFK 203, 204
HIV chemotherapy considerations 71
HMG-CoA reductase inhibition by compactin and lovastatin 50
Hormone-sensitive lipase (HSL, EC 3.1.1.3)
action
after high fat meal 171–173
after mixed meal 170, 171, 173
after overnight fast 169, 175
rate fluctuations 175
site of 164
activity measurement 165
in fat storage and mobilization 164, 175
Human
adenocarcinoma Caco-2 cells
glucuronidation of anti-cancer agents 91, 98, 99
adenocarcinoma Colo-205 cells
culture 92
depletion of MPA by 97, 99
adenocarcinoma HT29 cells
cloning studies 92
culture 92
glucuronidation of MPA 91
GTP synthesis inhibition by MPA 94, 95
recovery from 97, 98
proliferation, MPA on 94, 99
synthesis of MPAG in 95–97, 99
adenocarcinoma LoVo cells
culture 92
depletion of MPA by 97, 99
cAMP PDE type-IV 321–323
carcinoma MCF7 cells, glucuronidation by 98
carcinomas *ras* proto-oncogene activation in 49
colon carcinoma growth and metastasis inhibition by batimastat 296, 297
HeLa cells TK1 71, 73
leukemia AMOL cells TK1
properties 81, 82, 85
leukemia CCRF-CEM cells
CEM/VM-1 subline 267
at-MDR phenotype 274
multidrug resistance 274
topoisomerase IIα depletion in nuclear matrix 275
culture 267
topoisomerase II isozymes 270–278
leukemia Molt F4 cells
culture and incubation 254
me-MPR on DNA methylation and SAM concentration 257, 258
6MP cytotoxicity, synergism with MPA 253
6MP on DNA methylation and SAM concentration 257, 258
malignant ascites, batimastat clinical trial 298, 300
mammary carcinoma MDA-MB-435 cells
PI and PIP kinase activities in 8, 9
signal transduction, quercetin on 17
myeloblast leukemia ML-1 cells
basic characteristics and requirements 35
c-myb down-regulation by TPA 35
nuclear complex A analysis 38
ovarian carcinoma
malignant ascites growth inhibition by batimastat 296, 297
PI and PIP kinase activities in 7
OVCAR-5 cells
PI and PIP kinase activities in 7, 9, 14–17
signal transduction, quercetin on 14–17
promyelocytic HL60 cells TK1
properties 81, 82
PRPP synthetase
genes 233
chromosomal localization 235, 246
structure 235
homologies with rat 235
regulation of HSL and LPL
experimental procedures 165–167
mixed meal response 168, 170, 171
overnight fasting 167–170
thymidine kinase 1 (TK1, EC 2.7.1.21)
affinity control 72, 85
ATP effect 75, 76
cell-cycle regulation and 83, 85
enzyme concentration and 77
kinetic constants 79
reversibility 76
mechanism 84
ternary complex formation 78, 79
tetramerization 79, 80, 84
TdR concentration and 80, 85
defect regulation 71
dimer-tetramer fluctuation model 84
expression in *E. coli* 80, 86
from AMOL cells
ATP independence 82, 86
kinetics 81, 82
post-translational modification 82, 85, 86
from different cells 81
from HL60 cells
ATP independence 82, 86
kinetics 81, 82
post-translational modification 82, 85, 86

gene localization 70
kinetics 74
molecular weights 73, 74
effect of ATP 74
phosphorylation of AZT 70, 71
preparation 72
purification 73, 74
recombinant
independence of ATP 81, 84
post-translation modifications 82
preparation 72, 80, 81
tetramer form 81
S-phase regulated expression 71, 83–85
thymidine kinase II
chromosome location 70, 85
substrate specificity 70
Hydroxyl radical
detection 121
generation by mitomycins in EMT6 sonicates 125, 126
Hypoxanthine-guanine phosphoribosyltransferase (HGPRT, EC 2.4.2.8) in thiopurine metabolism 251, 252
Hypoxic stress protein p34 in tumors 112

IMP dehydrogenase (IMPDH, EC 1.1.1.205)
in thiopurine metabolism 251, 252
inhibition by MPA 253
$t_{1/2}$ by cycloheximide or tiazofurin 14
Inosine 5′-monophosphate dehydrogenase (IMPDH, EC 1.1.1.205) inhibition by MPA 91, 97
Inositide signalling in the nucleus 24
Inositol lipid cycle
effects of differentiating agents 31
nuclear signalling system 25, 29
Inostamycin
inhibition of CDP-DG:inositol transferase 45
isolation and structure 44
Insulin
activation of PDE isoforms 320
in post-prandial fatty-acid metabolism 171–175
on diabetic PKC isoforms 318
on fatty acid/TAG cycling 190, 191
on G-protein expression 319
on G_i-2 phosphorylation 312, 313
on VLDL TAG secretion 188, 189
-resistant states, adenylate cyclase regulation in 316, 318, 319
suppression of TAG lipolysis 187, 188
Insulin-like growth factor I, IGF-I
activation of nuclear PLC 28–30
requirements for ML-1 cell growth 35, 37, 40
stimulation of c-ets-1 protein 38, 39
Ion
concentrations in liver and hepatoma 105–107, 113
gradients
Gibbs-Donnan equilibrium system 111
maintenance in tumor cells 111
IP_3, inositol 1,4,5-trisphosphate
concentration in hepatomas of different growth rates 3
cycloheximide on 11
linkage with malignant proliferation 3, 19
metabolism 4
quercetin on 13–17
salvage pathway of production 18, 19
tiazofurin on 12
IP_6, inositol hexakisphosphate, phytic acid on salvage pathway for IP_3 4, 18, 20
Iron, role in inhibitory action of HCTs 63–66

K^+
concentration in liver and hepatoma 106, 111
-dependent phosphatase *see* Phosphatase
Ketogenesis, fatty acids for 184, 185, 187, 191, 192
Ketone body synthesis 185, 187, 192, 196
Kinase activator protein, relation to PDK2 157

Lactate
of liver and tumors 104, 105
production in tumors 110
Lactate dehydrogenase (LDH, EC 1.1.1.27)
expression in tumors 112
isozyme, hypoxic stress protein p34 112
Lavendustin A, tyrosine kinase inhibitor, structure 48
Lipase inhibitors in VLDL TAG metabolism 188–191
Lipoprotein lipase (LPL, EC 3.1.1.34)
action after
high fat meal 171–173
mixed meal 170, 171, 173, 175
overnight fast 169
activity measurements 164, 165

-derived fatty acids, possible fates of 167
generation of MAG 173
in fat storage and mobilization 164, 175, 176
release by heparin 165
site of action 164
synthesis by adipocytes 164
Lovastatin inhibition of *ras* function 50
Lyslendopeptidase (EC 3.4.21.50) digestion of synthetase protein PAP39 239

Magnetic resonance spectroscopy (MRS)
measurement procedure 103
P_i determination and tumor pH 101–103
rat liver and hepatoma
ion gradient calculation 108–110
lactate production 104, 105, 110, 112
pH_i and pH_e of 104, 105
tissue ion measurements 105–107
use of 3-aminopropyl phosphatase 105, 112
Malignancy
anabolic, catabolic imbalance in 251
DNA methylation in 258
m-AMSA (amsacrine)
at-MDR effect 274
inhibition of DNA ligation 266
mechanism of resistance 276, 277
resistance of CEM/VM-1 cells 274
Matrilysin (EC 3.4.24.23) inhibition by batimastat 295
Matrix metalloproteinase inhibitors *see also* Batimastat
as anti-metastatic agents 294, 300
as inhibitors of tumor growth 295–300
proposed clinical uses 298
6-Mercaptopurine (6MP)
chemotherapy 251
cytotoxic action 251–253
metabolism 251, 252
methylation 252
on DNA methylation and SAM concentration 257, 258
on SAM/SAH ratio in Molt F4 cells 255, 256
on transmethylation route 255, 257
synergism with MPA 253
Metastasis
agents against 294
before diagnosis 293
use of matrix metalloproteinase inhibitors 294
Methionine adenosyltransferase (MAT, EC 2.5.1.6)
activity in presence of 6MP and metabolites 255, 257
in transmethylation pathway 257
Methionine synthase (EC 2.1.1.13) in transmethylation pathway 257
Methylmercaptopurine riboside (me-MPR)
conversion to me-t-IMP 253
cytostatic action 253
inhibition of purine synthesis 253
on DNA methylation and SAM concentration 257, 258
Methyl-thio-inosine monophosphate (me-t-IMP)
cytotoxicity 253, 260
inhibition of PRPP amidotransferase 252, 253, 260
inhibition of purine synthesis 253, 260
on DNA methylation 257
Mg^{2+}
concentrations in liver and hepatoma 106, 107, 111, 113
gradient in liver and hepatoma 109
Microfilament
actin-based structure 199
regulation by actin phosphorylation 211–217, 224
Mitochondria
liver
glucagon on 133, 144
glutaminase in 132, 138
hormonal stimulation 138, 139
phosphate concentration in 134–137, 144
tumor 110, 111
Mitochondrial protein kinases 147
kinase domain structure 154
subdomains 154–156
relation to prokaryote histidine PKs 160
subunit composition 150
Mitomycin C
metabolism, comparison with porfiromycin 124–126
structure 122
toxicities to EMT6 cells, aerobic and hypoxic 121, 122
-X-irradiation combination therapy 118
Mitomycins
enzymes activating 118, 127
preferential action in hypoxic cells 117
Mofetil antitumor activity 91
Monoacylglycerol (MAG)
generation by LPL 173
hydrolysis 174
Monoacylglycerol (MAG)-lipase (EC 3.1.1.23) action in adipose tissue 174

Monoclonal antibody, (MoAb) PLC β1 28, 29
Mouse
carcinoma EMT6 cells
cloning studies 92
culture 92
GTP synthesis inhibition by MPA 94–98
inability to glucuronidate MPA 97, 98
proliferation, MPA on 94, 99
diabetes, adenylate cyclase regulating system 316–318
Ehrlich carcinoma
inhibition by inostamycin 45
inhibition by piericidin B_1 *N*-oxide 45, 46
erythroleukemia Friend cells, erythroid differentiation 24
changes of polyphosphoinositides and DAG 25
nuclear PLC
activity 25, 26
down regulation 28
identification of isoforms 28
leukemia L1210
cells
acetylated HCTs on 59, 61
3 and 5 substituted HCTs on 58, 60
DNA synthesis 62–64
in vivo
acetylated HCTs on 61, 62
3 and 5 substituted HCTs on 58–60
leukemia P338 cells resistance to daunorubicin 91
and glucuronidation ability 98
mammary tumor EMT6
culture 119
mitomycin C
stimulated O_2 consumption 125
toxicities, aerobic and hypoxic 121, 122
porfiromycin
stimulated O_2 consumption 125
toxicities, aerobic and hypoxic 121, 122
uptake 123
-X-irradiation treatment 119, 120, 123, 124
melanoma B16-BL6 cells lung colonization and tumor growth inhibition by batimastat 295–297
Swiss 3T3 cells proliferation PLC β1 activity 24, 29
Mycophenolic acid (MPA)
depletion by various cell lines 97
inhibition of GTP synthesis 94–98
inhibition of IMPDH 91
metabolism studies 93
on EMT6 cell proliferation 94
on HT29 cell proliferation 94
synergism with 6MP in Molt F4 cells 253
Mycophenolic acid O-glucuronide (MPAG)
HPLC analysis 93, 95, 96
mass spectrometry 93, 96
synthesis in HT29 cells 95, 96

Na^+
concentration in liver and hepatoma 106, 111, 112
gradients in liver and hepatoma 109, 113
NADH:cytochrome b_5 oxidoreductase (EC 1.6.2.2) reductive activation of mitomycins 118, 126, 127
NADPH:cytochrome P-450 oxidoreductase (EC 1.6.2.4)
reductive activation of mitomycins 118, 127
O_2 consumption measurements 125, 126
NAD(P)H:quinone oxidoreductase (DT-diaphorase, EC 1.6.99.2) reductive activation of mitomycins 118, 126, 127
Neomycin inhibition of actin polymerization 218
Non-esterified fatty acids (NEFA)
metabolism
after mixed meal 168, 171
after overnight fast 168
Nuclear matrix
association of topisomerase isozymes 274
depletion of topoisomerase IIα in drug-resistant cells 275, 276
general structure 265
in DNA replication 266
isolation from CEM cells 268
Nucleus
location of PLCβ1 in 30
purity checks 24, 27
Nutritional regulation of PI and PIP kinases 10

Okadaic acid
on G_1-2 phosphorylation 312, 313
stimulation of glutaminase 140, 141

Oncogene
activation from proto-form 43
interaction in ML-1 cells 39
products, tyrosine kinase association 47
Orobol, PI 4-kinase inhibitor, structure 46
Oxanosine
inhibition of *ras* function 50
structure 50

Palmitoyl-CoA on vesicle budding process 289, 290
PDEs *see* cAMP phosphodiesterase
pH of tumors
extracellular, pH_e
relative acidity 102, 104
intracellular, pH_i
historical view 101
similarity to normal tissues 102, 104
Phosphatase, K^+-dependent in hepatocyte secretory granules 284, 286
Phosphate, inorganic, Pi
in liver and hepatoma 106–108, 111
in liver mitochondria 134–137
MRS measurement and pH determination 102
on glutaminase 139, 140
Phosphatidylinositol (PI)
synthesis and S-phase induction 45
turnover inhibitors 44–47
CDP-DG:inositol transferase inhibitors 44–46
4-kinase inhibitors
on PI 3-kinase 47
structures 46
Phosphatidylinositol 4,5-bisphosphate (PIP_2,$PtdInsP_2$)
binding, actin-fragmin complex and 218, 219
capping activity 220, 224
dephosphorylation 222
nucleating activity 219, 220, 224
phosphorylation 217–220
stability 218
synthesis in differentiated nuclei 24, 25, 29
1-Phosphatidylinositol 4-kinase (PI kinase, EC 2.7.1.67)
activity
cell phase dependence 9
in human breast carcinoma cells 8, 9, 19
in human ovarian carcinoma 7, 9, 15, 19
in human ovary 7
in rat hepatomas 5–7
in rat tissues 5, 6, 18, 19
nutritional regulation 10
$t_{1/2}$ 11–14, 18
tiazofurin on 12, 14
in IP_3 metabolism 4
Phosphatidylinositol 4-phosphate (PIP, PtdInsP) increase during differentiation 25, 26, 29
1-Phosphatidylinositol 4-phosphate 5-kinase (PIP kinase, EC 2.7.1.68)
activity
cell phase dependence 9
in human breast carcinoma cells 8, 9, 19
in human ovarian carcinoma 7, 9, 15, 19
in human ovary 7
in IP_3 metabolism 4
in rat hepatomas 5–7
in rat tissues 5, 6, 18, 19
nutritional regulation 10
$t_{1/2}$ 11–14, 18
tiazofurin on 12, 14
Phosphodiesterases *see* cAMP phosphodiesterase
Phosphoinositides, possible role in microfilament regulation 217, 218
Phospholipase action in fatty-acid transfer 193
Phospholipase C (PLC, EC 3.1.4.2)
in differentiating Friend cell nuclei 25–28
nuclear isoform identification 28
immunochemical 28, 30
immunocytochemical 28, 30
monoclonal antibodies 28–30
nuclear isoform β_1
down regulation 28–31
possible chemotherapy target 30
5-Phosphoribosyl 1-pyrophosphate(PRPP)synthetase (ATP:D-ribose-5-phosphate pyrophosphotransferase, EC 2.7.6.1)
activation by trypsin treatment 243
-associated proteins (PAPs) 230
PAP39
amino acid sequence similarity to PRS I and II 239, 240, 246
evolutionary relationships 241
cloning 238, 239
enzymic activity unlikely 239–241
inhibitory function 242, 243
interaction with 34-kDa subunits 242, 243
proteolysis 242–245
mRNA in mammalian tissues 241
PAP41 244, 245

catalytic subunits
cDNA cloning 232, 233
possible functions 245
PRS I and II
amino acid sequences 234
similarity to PAP39 239–241, 246
molecular weights 233
rat, human homologies 235
recombinant
inhibition by nucleotides 237
properties 236
structural basis of difference between I and II 238
tissue differential expression 233
complex 230
gene structures 235
in nucleotide synthesis 229
nucleotide inhibition of native and recombinant subunits 237, 238
possible composition variation with tissue 241, 242, 246
purification from rat liver 230, 231
regulation of activity 229, 230
regulation of synthesis 230
sources 239
spatial arrangement of components 244, 245
subcellular distribution in liver 232
34kDa subunits 233
PAP39 interaction 242
resistance to proteolysis 243
Phosphorylation potential of tumors 110, 111
Physarum polycephalum
actin-fragmin complex 200, 201
actin-fragmin kinase isolation from 201, 223
extracts PP-1 and PP-2A activities 223
lysate proteins 205
PI kinase *see* 1-Phosphatidylinositol 4-kinase
Piericidins
inhibition of PI turnover 45
isolation and structure 44
PIP kinase *see* 1-Phosphatidylinositol 4-phosphate 5-kinase
Polyphosphoinositide cycle nuclear signalling system 27, 28
Porformycin
metabolism, comparison with mitomycin C 124–126
sensitivity differential of hypoxic and aerobic cells 124
structure 122
therapeutic advantage over mitomycin C 118
toxicities to EMT6 cells aerobic and hypoxic 121, 122
transport 121–124
uptake into aerobic or hypoxic EMT6 cells 123
-X-irradiation combination treatment 119, 123, 124
Post-prandial metabolism, reesterification of fatty acids 166, 170, 171
Profilin-actin complex 218
Protein diet on glutaminase level 133–137
Protein kinase A (PKA)
activation on G_i-2 phosphorylation 313, 315
activation of PDE isoform 320
activator Sp-cAMPS
glycogenolysis and 141, 142
stimulation of glutaminase 140–142, 144
antagonist Rp-8-Br-cAMPS
glycogenolysis and 141–143
inhibition of glutaminase stimulation 141, 143, 144
PKA II localization 306, 333
threshold and cAMP levels 304
Protein kinase C (PKC, EC 2.7.1.37)
activation by glucagon 310, 312
activation by hormonal stimulus 310
activity, link to cAMP production 304, 309
comparisons with AFK 203
isoforms expression in diabetes 316, 318
lipid signalling systems 309, 310
mediated phosphorylation of G_i-2 313
Protein kinases, nutritional control of 147, 148
Protein malnutrition
on BCKDK binding 158–160
on kinase activities 147, 148, 160
Protein phosphatase in G_i-2 phosphorylation cycle 312
Protein phosphatase 1 (PP-1)
actin-fragmin phosphatase activity 222
enhancement by PIP_2 222, 223
in *physarum* extracts 223, 224
properties 221
Protein phosphatases 2A (PP-2A)
actin-fragmin phosphatase activity 222
enhancement by PIP_2 222, 223
in *physarum* extracts 223, 224
of trimeric forms 222
properties 221
Protein phosphatases (Ser/Thr)
classification 221, 222
specificity for AFK phosphorylated actin sites 222, 224

PRPP amidotransferase (EC 2.4.2.14)
inhibition by me-t-IMP 252
consequences of 252, 253, 260
PRPP synthetase *see* 5-Phosphoribosyl 1-pyrophosphate synthetase
Purine metabolism
comparison with thiopurine 252
de novo synthesis inhibition by me-t-IMP 253
Pyridine-2-carboxaldehyde thiosemicarbazones
amino and hydroxy substituted
effects on CDP reductase 58, 60
role of iron 63–66
effects on DNA synthesis 62–64
effects on L1210 cell growth 58, 60
effects on mice bearing L1210 leukemia 58–61
structures 59
as anti-tumor agents 55, 56, 66, 67
Pyrimidine metabolism in neoplastic cells 69, 70
Pyruvate dehydrogenase (EC 1.2.4.1 + EC 2.3.1.12 + EC 1.8.1.4)
binding of PDK, protein malnutrition on 159
inactivation, enzymes for 147
inactivation of E1 156
Pyruvate dehydrogenase kinase (PDK, EC 2.7.1.99)
activity in starvation and diabetes 159–161
expression in *E. coli* 149, 156
isozymes of 148
p45 subunit (PDK II) 149
bound and free form 157, 158, 160
covalent modification 159
molecular cloning 152, 160
nucleotide and deduced amino acid sequences 153, 154
relation to kinase activator protein 157, 160
p48 subunit (PDK I) 148
molecular cloning 149, 160
nucleotide and deduced amino acid sequences 150, 151, 154, 160
protein sequence alignment with BCKDH 150–152
recombinant isoforms expression in *E. coli* 149
PDK I phosphorylation of PDEI 156
PDK II phosphorylation of PDEI 156
stable activity changes 147

Quercetin
on IP_3 13–17, 19
on MDA-MB-435 cell proliferation 17, 19
on OVCAR cell proliferation 16, 19
on PI and PIP kinase activities 13–17, 19

ras function inhibitors 49–51
structures 50
Rat
bone marrow, signal transduction in 10–14
diabetes, adenylate cyclase regulatory system 316–318
heart, cDNA amplification 150, 152
hepatocytes
fatty acid metabolism in 187
post-TGN secretory vesicles 283
characterization 284–287, 291
preparation for VLDL TAG studies 180–182
subcellular marker proteins 284, 286
VLDL TAG secretion 185–189, 194
hepatoma
3924A
IP_3 in 3
PI and PIP kinase activities in 5–7
5123 t.c. PI and PIP kinase activities in 5–7
7288 t.c. PI and PIP kinase activities in 5–7
7787 PI and PIP kinase activities in 5–7
8999
IP_3 in 3
PI and PIP kinase activities in 5–7
9618A
ATP content 108
ion gradients 108–110
IP_3 in 3
lactate of 104, 105
pH_i and pH_{139} of 104, 105
phosphorylation and redox state 107, 108
PI and PIP kinase activities in 5–7
tissue ion concentrations in 105–107, 112
water content 108, 109
H-35 (Reuber) cells
VAPP14 studies 288
vesicle-associated proteins 288
liver
ATP content 108
glutaminase 134, 135
ion concentrations in 105–107
ion gradients 108–110
IP_3 in 3

lactate in 104, 105
mitochondria 134, 135
pH_i and pH_e of 104, 105
phosphorylation and redox state 107, 108
PI and PIP kinase activities in 5–7
TAG/fatty acid cycle in 191, 192
water content 108, 109
liver PRPP synthetase *see also* PRPP synthetase
activation by trypsin treatment 243
gene structure 235
homologies with human 235
inhibition by nucleotides 237, 246
molecular mass 231
protein composition of 231
purification 230, 231
solubilization 232
spatial arrangements of components in complex 244, 245
subcellular distribution 232
PDE type IVA 323–328
Ribonucleotide reductase (EC 1.17.4.1) *see also* CDP reductase
activity imbalance leading to immune deficiency 69
allosteric regulation 71
inhibition by HCTs 55
mRNA PAP39 and PRS I levels in various mammalian tissues 241, 242, 244
Rolipram inhibition of type IV PDEs 306, 322, 323, 327, 331

SAH *see* S-Adenosyl-L-homocysteine
SAHH *see* S-Adenosylhomocysteine hydrolase
SAM *see* S-Adenosyl-L-methionine
Secretory vesicles
post-TGN identification 284
enzymes distribution 284, 286, 287
proteins associated 284, 286
ARF 284, 288, 289, 291
VAPP14 287–291
Sialtransferase
in hepatocyte secretory vesicles 284, 286
in hepatoma secretory vesicles 288
Signal transduction
glutaminase control and 139–144
inhibition and cancer chemotherapy 51
modification by oncogene products 43
regulation of 1–20
effect of starvation on 10
enzymes linkage with malignant proliferation 19
in bone marrow 10–13
in cell transformation 1
in hepatomas 6–10
in human breast carcinoma 8
in human ovary carcinoma 7
in rat organs 6
quercetin on 13–17
tiazofurin on 12
Signalling systems
cAMP 305
coupling to glucagon receptor 309
G_i-2 phosphorylation 311
SNARE hypothesis of vesicular transport 283, 291
Starvation, PDK activity in 159
Staurosporine inhibition of AFK 207
Streptomyces
PI turnover inhibitors from 44–47
tyrosine kinase inhibitors from 47, 48
tyrosine phosphatase inhibitor from 49
Stromelysoin (EC 3.4.24.17) inhibition by batimastat 295
Succinic dehydrogenase in hepatocyte secretory vesicles 284, 286
Sulfated proteoglycans
budding from TGN 288
in equilibrium density gradient 284, 287
in hepatocyte secretory vesicles 284, 285
GTP-binding protein (ARF) associated 284, 286
14kDa protein (VAPP14) associated 284, 286, 287
30kDa protein associated 284, 286
Superoxide
detection 121
generation by mitomycins in EMT6 sonicates 125, 126

Teniposide *see* VM-26
TGF-β (transforming growth factor-β)
effect on *c-myb* expression 37, 40
requirement for ML-1 cell differentiation 35, 40
suppression of c-ets-1 protein 39
6-Thioguanine (6TG)
chemotherapy 251
cytotoxic action 251
metabolism 251, 252
Thiopurine
antimetabolites in chemotherapy 251
metabolism 252
methylation by TPMT 252
Thiopurine methyltransferase (TPMT, EC 2.1.1.67)
in transmethylation pathway 257
methylation of 6MP 252, 257
methylation of thiopurines 252

Thymidine (TdR) effect on TK1 80, 85
Thymidine kinase (TdR kinase, TK, EC 2.7.1.21) *see also* Human thymidine kinase 1 and 2
preparation of recombinant 72, 73
$t_{1/2}$ by cycloheximide or tiazofurin 14
Thymidylate synthetase (EC 2.1.1.45)
chromosome location 70
Tiazofurin
induced differentiation in Friend cells 24
effect on nuclear PLC 27, 30
on IP_3 12, 19
on PI and PIP kinases 12, 14, 19
Tissue inhibitors of metalloproteinases 294
TIMP1 inhibition of angiogenesis 298
TIMP2 inhibition of transformed rat fibroblasts 297
TNF-α (tumor necrosis factor-α)
requirement for ML-1 cell differentiation 35, 40
Tolbutamide
on fatty acid/TAG cycling 190, 191
on VLDL TAG secretion 188, 189
Topoisomerase II *see* DNA topoisomerase II
Toyocamycin
inhibition of PI kinases 47
structure 46
Trans-Golgi network (TGN)
role of VAPP14 287–291
sulfate-transferring enzymes in 284–287
Transcription factors in *c-myb*
elongation 37–40
Transferrin (TF)
[^{125}I] in hepatocyte secretory granules 284, 286, 287
requirements for ML-1 cell growth and differentiation 35, 37–40
Transforming growth factor-β *see* TGF-β
Triacylglycerol (TAG)
accumulation 187
concentration on VLDL TAG output 185, 186
fatty acid cycling, effects of drugs 189–191
fatty acid transfer across ER membrane 193, 195
^{3}H and ^{14}C labeling 182, 188
human energy store 163
hydrolysis by LPL 173
in fat storage and mobilization 164, 175, 176
isolation of labeled 183
lipolysis, insulin suppression 187
measurement 182
measurements from human subjects 166
plasma after overnight fast 168
plasma transport 179
reesterification 188, 189, 196
transfer protein 180
transfer to incipient VLDL 180, 181
Trypsin (EC 3.4.21.4) treatment of PRPP synthetase 243, 244
Tumor
calcification 112, 113
cells, ion gradients in 111
growth inhibition by matrix metalloproteinase inhibitors 295–300
hypoxia 112
lactate production preference 110
necrosis factor-α *see* TNF-α
water content 108, 109
Tumors, solid, therapy problems from hypoxia 117
Tyrosine kinase inhibitors, structures 48
Tyrosine phosphatase inhibitors
role in signal transduction 48, 49
structures 49

UDP-galactosyl transferase in hepatocyte secretory vesicles 284, 286
UDP-glucuronosyl transferase (EC 2.4.1.17)
in P338 cells 91, 98
tissue locations 98

VAPP14 (vesicle associated peripheral protein)
budding process
antiserum on 289–291
F_{ab}-fragments on 289, 290
GTP-γ-s on 290, 291
palmitoyl-CoA on 289
detachment from membrane 288
location in sucrose density gradient 287, 288
relation to TGN-38 marker protein 288
Very low density lipoprotein (VLDL)
measurement 182
particle, schematic representation 180
preparation 180
synthesis in liver 179
TAG assembly
secretion in hepatocytes 185–187
chloroquin on 188, 189
insulin on 188, 189
pathological conditions 196
regulation 191–196
source of TAG 188, 196
tolbutamide in 188, 189
source of fatty acids 184, 192

VM-26 (teniposide)
interaction with topoisomerase II
isozymes 266
DNA binding 270, 271
IIα matrix target 273, 278
mechanism of resistance to 276, 277
stabilization of topoisomerase II-DNA complexes 271, 278
VP-16 (etoposide) inhibition of DNA ligation 266

White adipose tissue
fat storage and mobilization in 163, 164
fatty acid fluxes in 171, 172
fatty acid movement
regulation 174, 175
scheme 167
metabolism after overnight fast 169

X-irradiation in combination therapy
mitomycin C 118
porfiromycin, clinical trials 124
porfiromycin treatment of solid EMT6 tumors 123, 124
Xanthine:NAD^+ oxidoreductase (xanthine dehydrogenase, EC 1.2.1.37) reductive activation of mitomycins 118, 126, 127
Xanthine oxygen oxidoreductase (xanthine oxidase, EC 1.2.3.2) reductive activation of mitomycins 118, 126, 127